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I. INTRODUCTION
Twice as many women as men receive treatment for clinical depres-
sion, yet men benefit more than women from antidepressant drug treat-
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ment.1 Likewise, women use more prescription drugs than men, but
suffer proportionally more side effects.' Such disparities stem from the
traditional attitude of pharmaceutical companies and researchers to-
ward the use of women in clinical trials.3 In general, researchers have
tested drugs on young white males without regard for gender differ-
ences, 4 often assuming that data extrapolated from studies on males are
readily applicable to females.5 Even medical treatments designed exclu-
sively for women are developed and tested based on a male model, re-
gardless of the fact that women often react differently to many
treatments than men do. Researchers generalize information received
from male-oriented studies without sufficient information to show that
such treatments will be effective or safe for use by women. The net
result has been the marketing of drugs that are less effective for, and
1. Allen Raskin, Age-Sex Differences in Response to Antidepressant Drugs, 159 J. Nerv. &
Ment. Dis. 120, 120 (1974). In fact, one in five women will suffer serious clinical depression in her
lifetime. Elizabeth Sturt, N. Komakura and G. Der, How Depressing Life Is: Life-long Morbidity
Risk for Depressive Disorder in General Populations, J. Affective Dis. 109, 109 (Oct. 1984).
2. These side effects occur even after controlling for the dosage taken. Jean Hamilton and
Barbara Parry, Sex-Related Differences in Clinical Drug Response: Implications for Women's
Health, J. Am. Med. Women's Ass'n 126, 129 (Sept./Oct. 1983).
3. "Clinical trials" refers to two different kinds of studies. The first are large scale private
clinical intervention trials, used to study effective treatments for health problems such as heart
disease. Generally, these large trials are funded by the National Institutes of Health (NIH) subse-
quent to NIH approval of the study design. The NIH also funds public researchers for studies of
various health issues. The second type of clinical trials are used to determine the side effects and
efficacy of pharmaceutical products. These trials usually are conducted by private pharmaceutical
companies or by private researchers on grants from pharmaceutical houses. These studies must
conform to the Food and Drug Administration (FDA) regulations for clinical testing of drugs.
Women are systematically excluded from the first type of clinical trials, and women's health issues
generally are not addressed in these studies. See Part III.A.
The second form of clinical trials are governed by FDA policies which determine at what point
in the clinical trial fertile women can be included. See Part II.A. The net result of the FDA policy
is that fertile women often are not the subjects of clinical drug testing before the drugs are re-
leased into the market. See Wendy Chavkin and Harold Fox, Letter to the Editor, 264 JAMA 973
(1990).
4. Paul Cotton, Is There Still Too Much Extrapolation From Data on Middle-aged White
Men? 263 JAMA 1049, 1049 (1990).
5. Council on Ethical and Judicial Affairs, Gender Disparities in Clinical Decision Making,
266 JAMA 559, 559 (1991).
6. Id. The use of a male model is not unique to the medical profession. As Professor Lucinda
M. Finley stated:
[B]ecause pregnancy is in many significant respects different, its similarities to other human
conditions can be permanently elusive to legal decisionmakers. Even more problematic for its
application to gender issues, however, is the fact that equality analysis is inherently male-
biased. The search for sameness is built around male norms, so that what is male is the stan-
dard for measurement.
Lucinda M. Finley, Transcending Equality Theory: A Way Out of the Maternity and the Work-
place Debate, 86 Colum. L. Rev. 1118, 1181 (1986).
7. Council on Ethical and Judicial Affairs, 266 JAMA at 559 (cited in note 5). See generally
Cotton, 263 JAMA at 1049 (cited in note 4).
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often dangerous to, women.
Researchers and pharmaceutical companies historically have given
many reasons for their decision to use a male model in drug develop-
ment and testing." Increasingly, however, the medical community,
women's health organizations, Congress, and some administrative agen-
cies believe that the exclusion of women from clinical trials is a grave
oversight with potentially devastating consequences.' Recently, govern-
ment agencies and private organizations have taken steps toward en-
couraging pharmaceutical companies and researchers to include women
in clinical trials, but these efforts have had only moderate success.1"
Medical commentators urge that steps must be taken to ensure that the
treatment women receive is effective for their physiology. 1
Many legal issues surround both the failure to include women in
clinical trials and the steps necessary to rectify the consequences of this
omission. Either administrative action or traditional litigation could en-
courage pharmaceutical companies to take womens' health care more
seriously and, at the very least, to include women in their clinical trials.
Government regulation would provide the mandate for researchers and
pharmaceutical houses to include women in, their trials. Alternatively,
the cost of litigation itself might encourage pharmaceutical companies
to take such action without government interference.
This Note discusses the history and ramifications of the traditional
failure to include women in clinical trials and suggests a variety of
means by which pharmaceutical companies could be encouraged to in-
clude women in drug testing. Part II examines the reasons behind the
traditional exclusion of women from clinical trials, the justifications for
continuing that exclusion, and the ramifications of that exclusion for
womens' health care. Part III addresses the current efforts of the Na-
tional Institutes of Health, Congress, women's health organizations, and
the medical community to encourage pharmaceutical companies and re-
searchers to include women in clinical trials. Part IV discusses some of
the legal ramifications of the failure to include women in clinical trials,
including the liability of drug manufacturers for the release of drugs not
fully tested on women and the Equal Protection Clause issues sur-
rounding the exclusion of women from clinical trials. Part V suggests
the means, both legal and economic, by which the inclusion of women
in clinical trials could be achieved. This Note concludes that the inclu-
sion of women in clinical trials is necessary for effective health care and
8. See Part II.A.
9. See Part II.B.
10. See Part III.
11. See Council on Ethical and Judicial Affairs, 266 JAMA at 559-562 (cited in note 5).
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that the legal community should take steps to encourage pharmaceuti-
cal houses to rethink the way they currently test and market their
drugs.
II.- FROM NONTHINK TO SEXISM-THE HISTORY BEHIND THE DECISION
NOT TO USE WOMEN IN CLINICAL TRIALS
A. The Reasons for the Exclusion of Women from Clinical Trials
Researchers have given a variety of reasons for the exclusion of
women from clinical trials. The cornerstone of these theories is a belief
that, for testing purposes, women and men are essentially the same and
that any data obtained from the male physiology can be extrapolated to
the female. 2 This assumption, although apparently still popular, has
attracted severe criticism from the medical community.
13
Researchers often give a two-fold reason for the exclusion of
women that is antithetical to the primary assumption that extrapola-
tion is not only possible but easy. First, women, unlike men, introduce
complexities into the research that cause their inclusion in clinical trials
to increase the already exorbitant cost of those trials. 4 Second, phar-
maceutical houses fear liability for injuries to a woman or her fetus that
might occur in a clinical trial.' 5
Given the cost of clinical trials, researchers look for a sample popu-
lation that will present the most homogenous study group. Researchers
search for a sample population with the fewest confounding factors,'
6
which are thought to increase the complexity of the research.' 7 When
conducting clinical trials of drugs, researchers characteristically analyze
one or more variables while holding others constant. By using uniform
subjects, researchers believe they can determine more easily which of
the variable effects are caused by the drug itself.'8 Statistically, as the
sample population becomes more uniform, the results become more sig-
nificant in smaller sample sizes, and the research becomes less expen-
sive.' 9 The search for homogenous study populations has dominated
health care research and often has led to the exclusive study of white
12. Id. at 559.
13. See, for example, id.; Cotton, 263 JAMA at 1049-50 (cited in note 4); Chavkin and Fox,
264 JAMA at 974 (cited in note 3).
14. Cotton, 263 JAMA at 1049-50 (cited in note 4).
15. See Part II.A. Researchers have traditionally presumed that birth defects are passed
through the mother and not the father.
16. Council on Ethical and Judicial Affairs, 266 JAMA at 559 (cited in note 5).
17. Id.
18. Lynda Birke, Women, Feminism and Biology 57-58 (Methuen, 1986).
19. The more different subgroups are added to a study, the more complex, costly, and time-
consuming the study is likely to become.
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male subjects 20 based on the assumption that they are the most homog-
enous and readily extrapolated population." Critics believe that this
approach is erroneous since the specificity obtained from a homogenous
population ignores the natural complexity of biological events.22
Researchers generally do not perform studies on sample groups
containing only women, although in the name of homogeneity this
seems plausible. They claim that it is difficult to control for the hormo-
nal variations prevalent in women and that it would be nearly impossi-
ble to design an all-women study that produced clear answers.23 In
other words, female subjects present researchers with several con-
founding factors, including the menstrual cycle, pregnancy, teratogenic
liability24 and menopause. 25 Researchers consider these gender differ-
20. Many of the issues surrounding the relative lack of information on women's health issues
applies to minority populations as well. Studies have shown differences in the way African-Ameri-
cans, Asians, Hispanics and the elderly react to drug treatment. Nonetheless, these groups are also
traditionally excluded from the clinical trial arena in the quest for a homogenous study sample.
See Paul Cotton, Examples Abound of Gaps in Medical Knowledge Because of Groups Excluded
From Scientific Study, 263 JAMA 1051, 1051 (1990). Although many of the same concerns apply
to minority populations, a discussion of those ramifications is beyond the scope of this Note.
21. Dr. Jerry Avorn, a geriatrician and associate professor of social medicine at Harvard Uni-
versity Medical School, has said that this is an assumption made glibly and only because white
males run the country. Cotton, 263 JAMA at 1050 (cited in note 4).
Science, although ostensibly neutral and objective, is not always engaged in the disinterested
pursuit of truth, but is tied to the values of society at large-values which are male dominated.
Birke, Women, Feminism and Biology at 8 (cited in note 18).
22. Birke, Women, Feminism and Biology at 63.
23. Cotton, 263 JAMA at 1049-50 (discussing the effects of the menstrual cycle on drug
treatment).
24. Teratogens (from the Latin word meaning "monster") are agents that produce physical
or functional defects in the developing fetus. A teratogenic environment is created when a woman
is exposed to teratogens resulting in a birth defect in the fetus or a miscarriage. Edward Saunders
and Jeanne Saunders, Drug Therapy in Pregnancy: The Lessons of Diethylstilbestrol,
Thalidomide, and Bendictin, 11 Health Care for Women Int'l 423, 424 (1990). Teratogenic sub-
stances have been linked to embryonic or fetal death, stillbirth, cancer, and immediate or delayed
functional birth defects. See Felissa L. Cohen, Paternal Contributions to Birth Defects, 21 Nurs-
ing Clinics of N. Am. 49 (1986).
Mutagenic substances, on the other hand, are those that cause genetic alterations. Mutations
can occur in a number of cells and can result in damage to the parents, immediate offspring, or
future generations. Such alterations may or may not manifest themselves in the offspring of those
affected because they may be recessive. In order for recessive alterations to manifest themselves
both parents must have the mutated gene. Mutations, when manifest, can result in a number of
adverse outcomes such as impaired fertility, infertility, spontaneous abortion, congenital abnormal-
ities, birth defects, fetal death and cancer. Id.
There has been a significant amount of disagreement over the precise definition of teratogenic-
ity in both the regulatory and scientific fields. Some researchers include in their definition of ter-
atogens only those substances affecting the fetus from conception to birth. Others include the
period after birth, including effects occuring during reproduction and lactation as well. Addition-
ally, researchers are not clear which congenital defects are included as teratogenic effects. Some
only include damage to organ development, others include all physical manifestations including
central nervous system development defects, while still others include behavioral abnormalities as
well. Nanda Gilden and Henk Bodewitz, Regulating Teratogenicity as a Health Risk, 32 Soc. Sci.
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ences to be methodological problems rather than pertinent factors to be
studied.26 They assume that controlling for these factors would be too
complex or expensive, so they attempt to account for these differences
through extrapolation from males,27 often with disastrous results.28 The
notion of confounding factors is so ingrained in the clinical trial arena
that researchers even consider female rats too confounding to be
included.29
Additionally, the economics of health research financing often pre-
vent studies of women. The United States Department of Health and
Human Services through its arm, the National Institutes of Health
(NIH), awards large grants for health research and adds to the inequi-
ties inherent in clinical research."0 NIH administrators and scientific
advisors, most of whom are male, review proposals and assign priority
scores that determine the allocation of funding.3' These reviewers have
enormous discretion in determining who does or does not receive a
grant. Furthermore, the reviews determine the study conditions and the
& Med. 1191 (1991). Finally, due to a lack of properly designed studies, researchers often are not
certain whether a mutagenic substance will actually manifest in offspring-in other words, the
nexus between mutagenic and teratogenic effects of substances is not fully known to researchers.
C. A. Schreiner and H. E. Holden, Jr., Mutagens as Teratogens, in E. M. Johnson and D. M.
Kochhar, eds., Teratogenesis and Reproductive Toxicology, 65 Handbook of Experimental Phar-
macology, (Springer-Verlag, 1983).
For the purposes of this Note, the term "teratogenic" refers to what Doctors Gilden and
Bodewitz refer to as "reproductive toxicity," which includes all possible effects on the reproductive
process including effects on reproductive organs, conception, implantation, and fetal development.
Gilden and Bodewitz, 32 Soc. Sci. & Med. at 1193. Additionally, this Note assumes that substances
with mutagenic effects have the potential to be teratogenic as well, and are, therefore, substances
whose effects researchers wish to avoid.
25. Council on Ethical and Judicial Affairs, 266 JAMA at 559 (cited in note 5).
26. See note 23.
27. See Cotton, 263 JAMA at 1049-1050 (cited in note 4).
28. See Part II.B. Despite whatever concern drug manufacturers and researchers may have
for potential liability, drug manufacturers regularly market drugs with insufficient knowledge
about their products. The manufacturers do not know if their products will be harmful to women
due to the very factors that lead to the exclusion of women in the first place. The damage done by
this practice is that the medical profession is not informed about the differences in metabolism
and pharmacokinetics with regard to these drugs. Hamilton and Parry, J. Am. Med. Women's
Assoc. at 130 (cited in note 2).
29. Hamilton and Parry, J. Am. Med. Women's Ass'n at 130; Joan Hamilton and Peter Hong,
When Medical Research Is for Men Only, Bus. Week 33 (July 16, 1990).
30. See Mark V. Nadel, Summary of GAO Testimony by Mark V. Nadel On Problems in
Implementing The National Institutes Of Health Policy on Women in Study Populations 2, 4
GAO/T-HRD-90-38 (U.S. Gen'l Acctg. Office, June 18, 1990).
31. Id. at 4. Women's health issues have not fared well in the competition for research dol-
lars. For example, the National Cancer Institute, which has the largest budget of all the NIH
departments, spent 10.4% of its $1.2 billion budget on cancers unique to women. Since there are
no breakdowns on funding for men's diseases, such as prostate cancer, it is impossible to determine
if the expenditures for women's and men's health care have been equal. Id. at 9.
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manner in which the studies are conducted.2
The NIH prioritizes research topics annually, based on political
pressure or scientific fashion. The top bureaucrats are men. Only one-
third of the proposals approved after scientific review receive funding,
and the process of selecting proposals to fund is skewed to the detri-
ment of women. 3 The selection process favors those researchers who
have completed many projects successfully in the past.3 4 The more re-
search a particular investigator has conducted, the higher the priority
assigned to that investigator.3 5 Since women still constitute only a small
number of medical researchers, they submit fewer proposals.3 6 Further-
more, women who are researchers tend to be in the lower echelons of
the research hierarchy and, thus, have less extensive track records than
most of their male counterparts. 37 The low priority given to women's
health research may not change until women move into positions of
power, for instance as principal investigators of their own research or as
members of NIH panels. 8
The practice of extrapolating from the male physiology is even
more appealing to researchers since the Food and Drug Administration
(FDA) has prevented most clinical testing on fertile women unless a
substance is first tested either on men or on post-menopausal women.39
Furthermore, because of a desire to protect fertile women from damage
to their reproductive health or the health of their future offspring, the
FDA does not allow fertile women to be included before the final stages
of clinical trials, and then only after full teratogenic studies have been
run on animals.4 ° Many in the medical community argue that, since the
32. Id.
33. Id. While the mere fact that funding decisions are made by men does not in and of itself
mean that female researchers will get less consideration, a male in charge of the funding decision
would naturally give a higher priority to male diseases or diseases affecting both genders than to
predominantly female diseases.
34. Women Health Care Consumers: Short Changed on Medical Research and Treatment,
Hearing Before the House Subcommittee on Housing and Consumer Interests of the House Select
Committee on Aging, 101st Cong., 2d Sess. 80-81 (1990) (statement of Diana Petitti, M.D.).
35. Id. at 80.
36. See note 153.
37. Women Health Care Consumers at 81 (cited in note 34).
38. Cotton, 263 JAMA at 1049 (cited in note 4).
39. Chavkin and Fox, 264 JAMA at 973 (cited in note 3); Food and Drug Administration,
U.S. Department of Health, Education, and Welfare, General Considerations for the Clinical
Evaluation of Drugs 10-11 (Sept. 1977) ("FDA Guidelines").
40. FDA Guidelines (cited in note 39). See also Chavkin and Fox, 264 JAMA at 973 (cited in
note 3). For an interesting perspective on gender classifications protective of women, see Sylvia A.
Law, Rethinking Sex and the Constitution, 132 U. Pa. L. Rev. 955 (1984). Professor Law writes:
First, historically, biology provided a central justification for the subjugation of women. That
history partially explains the lack of focus on reproductive difference in contemporary equal-
ity doctrine and also suggests the need for close attention to such differences in developing
new ideas of equality. Second, "protection" of women-construction of the pedestal/
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FDA requires researchers to do all tests on males or infertile females
first, it is less costly simply to extrapolate from the data already re-
ceived than to run teratogenic studies on animals41 in order to include
fertile women in later clinical trials.42 According to many in the medical
community, this policy has resulted in the categorical exclusion of fer-
tile women from clinical trials of pharmaceutical products.
4 3
As a result of the exclusion of fertile women, drugs are manufac-
tured and marketed for use by those with the very confounding factors
deemed unwieldy in clinical trials." Because they do not study the im-
pact of these drugs on women systematically, researchers see the real
differences that exist between men and women only if they stumble
upon them later.45 Even in studies that include post-menopausal female
subjects, researchers seldom delineate differences between the gen-
ders.46 Since as many differences exist between various age groups of
cage-was a core mechanism for oppression of women. Contemporary feminists are hence
rightly skeptical of measures that protect women by providing them with special treatment.
Id. at 957.
41. Most studies are done on male animals. See text accompanying note 29. Besides the use
of only male animals in clinical trials of drugs, behavioral studies also are generally conducted on
male animals. For example, the research model for learned helplessness behavior, predominantly a
women's problem, was developed from a study conducted on male rats. Hamilton and Hong, Bus.
Week at 33 (cited in note 29).
42. Chavkin and Fox, 264 JAMA at 973-74 (cited in note 3).
43. One spokesman for the FDA, however, denies this allegation, claiming that women, even
fertile women, are included in many drug studies and claims to have data to support this view.
Telephone interview with Dr. Robert Temple, Director, Office of Drug Evaluation, Food and Drug
Administration (January 10, 1992). Dr. Temple cited a recent study of the antidepressant drug
Citrolene in which the overall study population included 60% females. During the later phases of
the clinical trials, the population of those under 45 years of age was half male and half female, and
included fertile women. Fertile women were not included in the early phases of the clinical trials of
Citrolene. Id.
Although the main focus of the Citrolene study was age distribution, most respondents also
disclosed their gender. Overall, women represented at least 28% of the study population, but how
many of those women were fertile is unknown. Robert Temple, Studies of Older Patients in NDA's
for NMEs Approved in 1988, 4 (Sept. 8, 1989) (unpublished memorandum, on file with the Van-
derbilt Law Review). The studies cited by the FDA spokesman were designed to measure the num-
ber of older people involved in the studies-that the breakdown was also by gender was simply a
fortuitous side effect of the studies. Id. Since the studies were broken down by age, the FDA does
not know whether the women involved in the studies were pre- or post-menopausal. Id. In order to
obtain a clear understanding of the extent of participation of fertile women in clinical trials, the
FDA asked the General Accounting Office to make a study of a large number of clinical trials. Id.
The information from these studies should be available later this year, but Dr. Temple is fairly
certain that the statistics will show that even fertile women are included in clinical trials. Id.
44. Cotton, 263 JAMA at 1050 (cited in note 4) (quoting Michelle Harrison, assistant profes-
sor of psychiatry at the University of Pittsburgh).
45. Id. (quoting Jean Hamilton, M.D., Director of the Institute for Research on Women's
Health, in Washington D.C.).
46. Telephone interview with Dr. Temple (cited in note 43); Hamilton and Parry, J. Am.
Med. Women's Ass'n at 126 (cited in note 2).
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women as between the genders themselves," the inclusion of older
women has done little to resolve the dearth of understanding of
women's cycles. As one medical commentator has pointed out, so far
researchers have stumbled upon only a tiny fraction of the numerous
medical differences between the genders.48
B. The Impact of the Exclusion on Women
As a result of the traditional notions surrounding women and drug
testing, drug manufacturers and researchers have excluded women from
many clinical trials in which the need for their inclusion would seem
self-evident. For example, researchers recently excluded women from
several significant clinical intervention trials on heart disease. Although
heart disease is the number one killer of women as well as men,49 re-
searchers excluded women because, as a whole, the medical profession
views heart disease as a typically male disease. 50 Furthermore, women
are excluded from such studies because, on the average, heart disease
strikes them ten years later than it strikes men.51 In order to study
heart disease in women effectively, researchers would need to study ex-
perimental female subjects for longer periods of time than male sub-
jects, increasing the cost of the study.2
Despite these problems, some researchers have shown that women's
menstrual cycles may be the reason women suffer heart disease later
than men.5 These scientists think that the menstrual cycle probably
protects women from early heart disease and, therefore, that it may be
possible to treat women's heart disease with dosages of estrogen.54 Since
estrogen once was tried as a treatment for male heart disease with nega-
tive results, 5  researchers have not resumed such treatment for women's
47. Raskin, 159 J. Nerv. & Ment. Dis. at 120-28 (cited in note 1).
48. Cotton, 263 JAMA at 1050 (cited in note 4) (quoting Jean Hamilton). The National
Women's Health Network believes that the exclusion of women is an oversimplified method of
avoidance with many negative consequences and that the exclusion of women is both ironic and
dangerous since women will be using the same products which are too dangerous to be tested on
them. National Women's Health Network Research to Improve Women's Health: An Agenda for
Equity 5 (Dec. 1991) (unpublished position paper, available from the National Women's Health
Network, 1325 G St., N.W., Washington, D.C. 20005).
49. Cotton, 263 JAMA at 1051 (cited in note 20).
50. Lawrence Altman, The Doctor's World: Men, Women and Heart Disease: More Than a
Question of Sexism, N.Y. Times Cl, col. 4 (Aug. 6, 1991).
51. Cotton, 263 JAMA at 1051.
52. Id.
53. See Altman, The N.Y. Times at C1 col. 4 (cited in note 50).
54. Id.
55. For example, artificial estrogens, such as DES, were used. While they did decrease the
chances for heart disease, they resulted in extreme feminization of the males involved and pro-
duced detrimental effects on their reproductive capacity. Roberta Apfel and Susan Fisher, To Do
No Harm: DES and the Dilemmas of Modern Medicine 19 (Yale, 1984).
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heart disease regardless of the indications of possible success.56
Similarly, when cholesterol studies emerged linking low density
lipid (LDL) cholesterol levels with heart disease, the medical commu-
nity recommended cutting back on the number of fats and the amount
of cholesterol in the diet, and the nation responded. The original stud-
ies of cholesterol, however, were performed exclusively on males.57 Sub-
sequent studies of women's heart disease suggest that high density lipid
(HDL) cholesterol levels, which are also reduced by a low-fat diet, actu-
ally can protect premenopausal women from early heart disease.5 8 Thus,
women might be at a greater risk by lowering both their LDL and HDL
cholesterol levels than they would be by allowing both to remain high.5 9
In addition, the lack of data regarding cholesterol and women's health
suggests the need to investigate the effects of oral contraceptives, which
potentially can cause excessive amounts of cholesterol in the blood.
6 0
No information exists regarding the efficacy of cholesterol lowering
drugs when combined with oral contraceptives.
6 1
The lack of knowledge and research on women's health issues gen-
erally has led to two major problems for women's health care. First,
doctors and researchers are unaware of many negative side effects
unique to women triggered by commonly used prescription drugs. Sec-
ond, due to the exclusion of women from large studies, many beneficial
effects of common drugs are documented for men, while little informa-
tion exists regarding similar beneficial effects for women.
Although twice the number of women suffer from clinical depres-
sion as men, researchers have based the study and the development of
antidepressants almost exclusively on a male model.6 2 After drug com-
panies released many antidepressants commonly used for treatment,
doctors conducted studies to determine whether age and gender differ-
ences existed in response to these drugs.6 3 These studies revealed that
women responded to various drugs differently at different points in the
menstrual cycle. 4 Ironically, the menstrual cycle was the very justifica-
tion for excluding women from the clinical trials of these drugs in the
first place.6" The studies showed that some antidepressants had an ex-
56. Id.
57. Cotton, 263 JAMA at 1055 (cited in note 20).
58. Id.
59. Id.
60. The presence of unusually high amounts of cholesterol in the blood is known as
hypercholesterolemia. Tabers Cyclopedic Medical Dictionary 860 (F. A. Davis, 16th ed. 1989).
61. Cotton, 263 JAMA at 1055 (cited in note 20).
62. Hamilton and Parry, J. Am. Med. Women's Ass'n at 130 (cited in note 2).
63. Raskin, 159 J. Nerv. & Ment. Dis. at 120-130 (cited in note 1).
64. Id.
65. Council on Ethical and Judicial Affairs, 266 JAMA at 559 (cited in note 5).
[Vol. 45:877
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tremely negative psychological impact on some women during certain
points of their menstrual cycle, causing them to become depressive at
one point and violent at another.6 Drugs designed to produce a eu-
phoric effect were successful in males, but tended to cause females to
become violent and hostile.6 7 Due to premenstrual exacerbations of de-
pression, a uniform dose over the entire menstral cycle may be too high
during the first part of the cycle and too low later in the cycle .6 This
example of pharmacokinetic variation69 during menstruation illustrates
the lack of clinical understanding of women's cycles.70 Most doctors
must come to these conclusions on their own since they are rarely in-
cluded in the literature on pharmaceutical products.7'
Women also suffer proportionately more negative side effects than
men, even though men often will have more drug accumulation. 72 As
two clinical psychiatrists have observed, researchers often will use an
inappropriately small sample size, one which either does not include
women or does not separate data by gender, in determining reactions to
various drugs.73 Thus, there is a tendency to conclude that no sex dif-
ferences exist, a danger made more apparent by the failure to take pos-
sible menstrual-related effects into account.74
When studies show that drugs have beneficial effects on men, the
lack of knowledge concerning the female physiology leads to uncer-
tainty as to whether there will be similar beneficial effects on women.
The primary example of this sort of uncertainty is the massive aspirin
study conducted in 1981, which used 22,000 male physicians as test sub-
jects.75 The results of the aspirin study showed that men can reduce
their risk of heart disease if they take aspirin every other day.76 Accord-
ing to the study, the effects of a similar dose of aspirin for women were
inconclusive.77 Stating that the study was inconclusive as to the effects
66. Raskin, 159 J. Nerv. & Ment. Dis. at 120-130 (cited in note 1).
67. Id.
68. Cotton, 263 JAMA at 1051 (cited in note 20).
69. Pharmacokinectics refers to the action of drugs in the body.
70. Cotton, 263 JAMA at 1051 (cited in note 20). According to Michelle Harrison, M.D.,
assistant professor of psychiatry at the University of Pittsburgh, doctors do not know if drugs are
being metabolized differently or whether women innately need a higher dosage at different times
in their cycle. Id. Margaret Jensvold, M.D., in private practice in Bethesda, Maryland, noted that
findings regarding the dosage levels in women's menstrual cycles rarely are made in the literature,
although physicians often come to the same conclusions on their own through trial and error. Id.
71. Id.
72. Hamilton and Parry, J. Am. Med. Women's Ass'n at 128 (cited in note 2).
73. Id. at 130.
74. Id.
75. Hamilton and Hong, Bus. Week at 33 (1990) (cited in note 29).
76. Id.
77. Peter L. Frommer, M.D., Deputy Director of the National Heart, Lung, and Blood Insti-
tute in Bethesda, Maryland, contended that even had women been included, the Institute "would
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on women suggests that the data on women was difficult to interpret,
but in fact the study was inconclusive for women because women were
not studied at all.7 s Researchers presumed not only that there were not
enough female physicians to make an effective study, but that female
physicians would not have wanted to undergo the inconvenience of tak-
ing a placebo.79 Doctors attempted to extrapolate from the aspirin data
on men, but ultimately were unable to do so safely since aspirin also
produced many negative side effects in women. 0
Years later, researchers determined that aspirin also might have a
beneficial effect for women and ran a nonclinical, observational trial on
several thousand nurses.8 ' The study revealed that aspirin did indeed
have beneficial effects for women.8 2 However, because the study was ob-
servational, not clinical, its validity is questionable. 3 Since that time,
the effect of aspirin on women's heart disease, as well as the beneficial
effects of drugs on other diseases that affect women significantly, have
not been studied with the same intensity as the traditional male
diseases.8 4
The concern of FDA regulators and clinical researchers that drugs
might have teratogenic effects stems from the most striking example of
teratogenic liability in this country-the diethylstilbestrol (DES) crisis.
DES was first prescribed in America in 1943, but its efficacy was chal-
lenged as early as 1953.85 In 1971, the FDA banned the use of DES
during pregnancy as a result of DES's carcinogenic properties in the
offspring of DES mothers. 6 DES use became common shortly after
have ended up shrugging [its] shoulders," because the number of female physicians is much
smaller and a smaller number would have heart attacks. Cotton, 263 JAMA at 1055 (cited in note
20).
78. Hamilton and Hong, Bus. at 33 (cited in note 29).
79. Cotton, 263 JAMA at 1055 (reporting the comments of Peter Frommer, M.D.) (cited in
note 20). Why female physicians would be less willing to inconvenience themselves is not clear.
Additionally, the logic behind excluding women because there were not enough female physicians
to make an effective study does not hold up since similar research was later conducted on nurses.
80. Id.
81. Lawrence Appel and Trudy Bush, Preventing Heart Disease in Women: Another Role
for Aspirin, 266 JAMA 565 (1991).
82. Id.
83. Id. Observational studies are based on observation and on data given to the researcher by
the subjects in the experiment. Since such studies-are not conducted in a clinical setting, it is
possible that a variable other than the one being studied is the cause of the change. In order to be
absolutely certain of the potential beneficial effects of aspirin in women, a randomized, controlled
clinical trial is necessary. Id.
84. National Women's Health Network at 3 (cited in note 48). The Network argues that the
male dominated nature of scientific research is the reason women's health issues have received
short shrift.
85. Saunders and Saunders, 11 Health Care for Women Int'l at 424-25 (cited in note 24).
86. Id.
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World War II, when one in every four pregnancies was unsuccessful.8 7
DES was used to prevent spontaneous abortions, miscarriages, and pre-
mature birth."" Initially DES was prescribed only for women with at
least one prior unsuccessful pregnancy, but it later became a common
prescription drug for any woman thought to be at risk of miscarriage.
An estimated three million women eventually were treated with it.s9
The offspring of DES mothers felt the adverse consequences of DES,
mostly in the form of birth defects and cancer.9 0 As a result of the DES
crisis, the FDA almost immediately tightened its standards for drug
testing, requiring among other things that a drug be efficacious for the
purpose for which it is used.9
The results of DES use were tragic and devastating for the women
involved. There is no guarantee, however, that the DES crisis will not
be repeated. 2 It was not tested on animals for teratogenic potential, nor
were dose-ranging studies93 run to determine safe dosages or side ef-
fects. Probably in response to the DES crisis, the FDA implemented
regulations making it very difficult to test drugs on fertile women. Fer-
tile women can be tested only after the dose-ranging and efficacy stud-
ies have been completed and only after teratogenic animal studies have
been run. 4 As a result of the additional costs inherent in compliance
with these rules, drug manufacturers choose to release many drugs
without testing them on women and with no knowledge of their possible
teratogenic effects. Currently the best advice the medical community
can give to women is to avoid all drugs during pregnancy unless not
taking them would put the fetus at greater risk than taking them. 5
87. Id. at 424.
88. Apfel and Fisher at 26 (cited in note 55) (reprinting an ad for DES appearing in a medi-
cal journal and making these claims).
89. Saunders and Saunders, 11 Health Care for Women Int'l at 425 (cited in note 24).
90. In the female offspring of DES mothers, a rare form of vaginal and uterine cancer, clear
cell adenocarcinoma, developed; structural defects of the cervix, vagina, uterus, and fallopian tubes
were discovered; adenosis and dysplasia of the cervix, infertility, adverse pregnancy outcomes such
as spontaneous abortions, ectopic pregnancies, premature deliveries, and perinatal deaths have oc-
cured. Also, there is evidence to show that male offspring of DES mothers are more likely to be at
risk of anatomic abnormalities of the penis and testes and at an increased risk for reproductive
dysfunctions. Id.
91. Id. at 429. Such a regulation would have prevented the marketing of DES.
92. Id. at 430.
93. Dose-ranging studies are used to determine the efficacy and safe dosage levels of lrugs.
The tests are run on large laboratory animals, such as monkeys or dogs, to determine the margin of
safety-the difference between a lethal dose and no effect at all. The first phase of clinical trials on
human beings is used to determine a safe dosage range as well as any negative side effect. Richard
Ausness, Unavoidably Unsafe Products and Strict Products Liability: What Liability Rule
Should be Applied to the Sellers of Pharmaceutical Products? 78 Ky. L. J. 705, 731 n.166 (1989-
90).
94. FDA Guidelines at 10-11 (cited in note 39).
95. Saunders and Saunders, 11 Health Care for Women Int'l at 430 (cited in note 24). Saun-
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III. CURRENT EFFORTS TO RECTIFY THE KNOWLEDGE GAP
A. The NIH's Policy to Encourage the Inclusion of Women
According to many in the medical profession, the quest for a ho-
mogenous study population has created a myopic view of clinical re-
search.96 This view continues to prevent medical research from being
truly effective for the majority of the population.97 In order to address
this problem, the Public Health Service (PHS), an arm of the Depart-
ment of Health and Human Services, created a task force to investigate
the inequities in women's health care research.9 8 The PHS task force
issued a report which listed five criteria to determine whether a particu-
lar disease was a women's disease: first, the condition must be unique to
women or some subgroup of women; second, it must be more prevalent
in women or some subgroup of women than in men; third, it must be
more serious in women or some subgroup of women than in men;
fourth, the condition must be one for which risk factors are different for
women or some subgroup of women than for men; or fifth, it must be
one for which treatment interventions are different for women or some
subgroup of women than for men. 9 If any of the criteria are met, then
the disease is considered an important women's health issue, and these
five criteria remain the current definition for women's health issues.100
Once a women's health issue was targeted, the PHS report made
two recommendations for improved research. First, researchers should
expand biomedical and behavioral research to assure emphasis on con-
ditions and diseases prevalent in women of all age groups.' Second,
researchers must make a systematic effort to address the issues relating
ders and Saunders specifically recommend:
(1) No drugs should be taken by a pregnant woman or lactating mother unless specifically
approved by her obstetrician-gynecologist or her infant's pediatrician. (2) If drugs are re-
quired for a certain condition, the safest drugs at the lowest effective dose should be used. (3)
Although it is best to use no drugs during pregnancy, there are a number of medical condi-
tions-like diabetes-that, if left untreated, can put the fetus in considerable jeopardy. In
these instances, the risks of the diseases are greater to the fetus than the risks of the drugs
required to treat them. . . (4) Assume nothing, ask questions, and be honest with yourself
and your physician. This guideline strongly encourages women to assume an active role in
their care.
Id.
96. Cotton, 263 JAMA at 1049 (cited in note 4).
97. In 1989, women constituted 51.2% of the population. The entire population of the
United States was estimated at 248,762,000 of which 127,317,000 were women. Bureau of the Cen-
sus, U.S. Dep't of Commerce 13, Statistical Abstract of the United States 1991 (11th ed. 1991).
98. See Nadel, Summary of GAO Testimony at 1 (cited in note 30).
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to gender bias in research.' °2
The Public Health Service agencies, with the exception of the NIH,
have largely ignored these recommendations.' 03 The NIH, however, did
establish the Women's Health Advisory Committee (the Advisory Com-
mittee) to make suggestions on possible ways to implement the PHS
report's recommendations. 10 The Advisory Committee made a policy
recommendation that the NIH adopted in 1986, urging applicants to
include women in any clinical test for which they wanted NIH fund-
ing.'0 The new policy further requested that researchers who do not
include women give reasons for their exclusion.', Additionally, the
NIH's policy requested that researchers evaluate gender differences
specifically in their findings.1
0 7
Although the NIH instituted its policy with the hope that it natu-
rally would lead to the inclusion of women in clinical trials, the NIH
did little to enforce the policy. 08 In fact, the NIH did not publish
guidelines for implementing the program until 1989.109 It is not clear
whether the policy has been even moderately successful in accomplish-
ing its stated goal.
In 1989, the Congressional Caucus on Women's Issues asked the
General Accounting Office (GAO) to verify whether NIH grant appli-
cants were adhering to the NIH policy."0 Specifically, the Caucus
wanted to know whether the NIH had denied any grant applications on
the basis that the study population did not include women, or in the
alternative, whether the NIH had granted any waivers. ' When it filed
its report the next year, the GAO determined that the NIH had made
little progress in implementing its policy.1 2
The GAO found three reasons for this lack of success. First, the
policy had not been communicated within the NIH itself and had been
applied inconsistently among the institutes."13 The policy was not used
102. Id. at 11-12.
103. Id.
104. Nadel, Summary of GAO Testimony at 3 (cited in note 30).
105. Id.
106. Id.
107. Id. The report concluded that 13.5% of the NIH budget had been spent for women's
health issues but rather contended that this did not mean that the remainder of the money was
spent on men's diseases. The NIH stated that the majority of funds was spent for the study of
diseases that affect both genders. Women Health Care Consumers at 84 (cited in note 34) (state-
ment of William F. Raub, Ph.D., Acting Director of the NIH).
108. Nadel, Summary of GAO Testimony at 3.
109. Id.
110. Cotton, 263 JAMA at 1050 (cited in note 4).
111. Id.




by some institutes in reviewing research applications until 1991, one
year after the GAO report."4 The GAO found that the NIH had actu-
ally undermined its own policy by not considering the inclusion of
women as a key factor in determining the scientific merit of a proposed
study."5 The Division of Research Grants, which is responsible for re-
viewing upcoming grant applications, had directed its reviewers not to
consider compliance with the NIH policy until the scientific merit of
the study had been assessed." 6 The GAO stated that the failure to con-
sider the study population as a factor in determining scientific merit
downgraded the importance of the policy.
117
Second, the NIH had taken no action to assist or encourage re-
searchers to analyze conclusions by gender." 8 To the extent the policy
was implemented, it dealt entirely with ending the exclusion of women
from study populations, but did not focus on whether diseases and
treatments affect men and women differently." 9 Third, the NIH could
not demonstrate the policy's effect since no readily accessible source of
data on the demographics of NIH study populations exists. Therefore,
an evaluation of the policy's effect on studies completed after 1987 is
impossible, and the NIH was unable to provide the GAO with informa-
tion on previously funded all-male studies.2 0 Finally, the NIH applied
its policy only to outside studies, not to studies actually conducted by
the NIH institutes.'
2 '
The GAO recommended that the NIH inform both its staff and the
researchers who receive NIH funding of the reasons for the policy.12
2
The GAO stated that the NIH grant applications should be revised to
include the policy and instructions requiring applicants either to in-
clude women or to justify their exclusion.' 2 ' The GAO also recom-
mended that the NIH instruct scientific review groups to determine
whether the gender of the study population is scientifically relevant. 124
The NIH then would maintain this data in some readily accessible
form. "'25 In spite of the GAO's report, the deputy director for the NIH's
National Heart, Lung, and Blood Institute, which funded the large
114. Id. at 5 (cited in note 30).
115. Id. at 9.
116. Id.
117. Id.
118. Id. at 11.
119. Id.
120. Id. at 11-12.
121. Id. at 10.
122. Id. at 12.
123. Id. at 13.
124. Id.
125. Id. at 12.
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clinical intervention trials on heart disease from which women were ex-
cluded, challenged those who question the policy's effectiveness to
demonstrate how the NIH has been derelict.1 2 6
The NIH did take steps in response to the GAO report. In 1990,
the NIH established the position of Associate Director for Research on
Women's Health and authorized it to monitor the institutes of the
NIH.'2 7 The NIH also altered its policy to include a mandate that re-
searchers either include women in clinical research or justify their ex-
clusion.'28 Despite the flurry of activity that has occurred in the wake of
the GAO report, the NIH's enforcement of the policy has continued to
be lax and only recently has Bernadine Healy, the current director of
the NIH, begun to enforce the policy.'29
The NIH's failure actively to enforce its policy parallels the atti-
tude adopted by the FDA. Both entities seem to think that pharmaceu-
tical companies will do voluntarily what is necessary to ensure that
their products are suited for various subgroups. '30 Thus, both agencies
may think that they do not need to take a more active role."' Further-
more, since NIH grants affect only those who do not receive funding
from private pharmaceutical houses, some have questioned the extent
to which NIH policies actually have changed the way large pharmaceu-
tical houses do business.' 32
B. Congress's Initial Efforts to Rectify the Exclusion
Congress also has attempted to rectify the knowledge gap concevn-
ing women through legislation. In 1989 the Congressional Caucus for
Women's Issues developed a set of bills called the Women's Health Eq-
uity Act of 1990.13 In 1991 the House of Representatives passed the
bill, which would create an Office of Research on Women's Health.1 34
The House designed the Office to address women's health issues and to
rectify the differential treatment given women in many areas of the
126. Cotton, 263 JAMA at 1050 (cited in note 4) (reporting statements by Peter L. Frommer,
Deputy Director of the National Heart, Lung and Blood Institute).
127. Women Health Care Consumers at 105-06 (cited in note 34) (letter of Ruth Kirschstein,
M.D., Acting Associate Director on Women's Health at NIH).
128. Id. at 105.
129. See Bernadine Healy, Women's Health, Public Welfare, 266 JAMA 566 (1991).
130. Cotton, 263 JAMA at 1049 (quoting FDA spokesman Mike Shaffer).
131. But see Healy, 266 JAMA at 566 (cited in note 129).
132. Id. An industry spoksman, Lionel Edwards, M.D., chair of the Pharmaceutical Manufac-
turers Association's new Special Populations Committee, noted that studies could be "subgrouped
to death." Id. More than 50% of the population is a large subgroup to ignore, however.
13:3. The Act was resubmitted as the Woman's Health Equity Act of 1991 for the 1991-92
congressional session, S.514, 102d Cong., 1st Sess. (1991).
134. National Institutes of Health Revitalization Amendments of 1991, H.R. 2507, 102d




In order to accomplish this goal, the director of the Office would
identify projects of importance to women's health that the NIH should
fund. 3 ' The director also would make recommendations on the best
agenda for supporting such projects 3 7 and promote the proper alloca-
tion of resources to such projects. 38 In addition, the Office would take
active steps to insure the inclusion of women in clinical research. 139
The House included some parts of the Women's Health Equity Act
in its NIH revitalization amendments with the express intent of ad-
dressing issues surrounding women's health care.14 ° The Senate's ver-
sion of the Women's Health Equity Act contains many of the same
elements as the House bill, although it has yet to come to a full vote
before the Senate.' The purpose of both the Senate and House ver-
sions is to insure that women's health issues, such as breast cancer,
which affect a large and growing number of women annually are not left
unaddressed by the medical and research communities.1 42 The Women's
Health Network hopes that Congress will pass this legislation, since it
would be a major step forward for women's health research.
43
Despite these halting steps taken by Congress, many in the medical
community believe that if anything is to be done about the failure to
include women in clinical trials, it will have to be done by women. 
1 4
Commentators recognize that the odds are against those who wish to fill
these gaps in clinical research data.145 Only seven years after its adop-






140. Id. The bill also would create an Office of Research on Women's Health to address the
mental health and substance abuse concerns of women. Id. § 142, in 137 Cong. Rec. H5849. Addi-
tionally, the bill would authorize a $50 million grant specifically for breast cancer research. Id. §
501, in 137 Cong. Rec. H5855. The bill would provide for $5 million for the development and
operation of fertility research centers and protocols for training physicians, scientists, nurses and
other health professionals. Id. §§ 901, 902, in 137 Cong. Rec. H5856. This portion of the bill was
included in the House and Senate NIH reauthorization bills, although the language was taken out
of the Senate bill prior to passage. The bill also would authorize and fund projects on women and
AIDS research, Id. tit. XV, in 137 Cong. Rec. H5860, and other important women's health issues.
141. S.514, 102d Cong., 1st Sess. (1991).
142. The preamble to this bill announces that the bill will "promote greater equity in the
delivery of health care services to women through expanded research on women's issues, improved
access to health care services, and the development of disease prevention activities responsive to
the needs of women." Id.
143. National Women's Health Network at 18-19 (cited in note 48).
144. Cotton, 263 JAMA at 1050.
145. Cotton, 263 JAMA at 1049.
146. Id. at 1050.
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many are concerned that the NIH policy will stagnate as well if it is not
enforced effectively.14 The apparent lack of decisive action on the part
of government agencies has led doctors and women's health groups to
assume that the increasing number of female researchers now entering
the medical field will have to rectify the inequalities'4" by taking leader-
ship roles in their own research projects. 49 Although the current Direc-
tor of the National Institutes of Health is a woman, the need for
additional women in leadership positions has yet to be fulfilled.1 50
IV. THE LEGAL RAMIFICATIONS OF EXCLUSION
A. Equal Protection Under the Law and the FDA Guidelines
After expense, the most cited reason for the exclusion of women
from clinical tests is the fear of teratogenic liability. Researchers and
the FDA are concerned that clinical tests could harm irreparably a wo-
man's capacity to bear children or cause harm to the fetus itself.1 5 '
Since a woman provides the gestation environment for a fetus, research-
ers fear that clinical tests could create a teratogenic environment-one
that could lead to serious birth defects on the scale suffered by the
Thalidomide babies in Europe. 52 On the assumption that drug-related
birth defects come from the mother,1 53 scientists traditionally cited con-
cern about fetal damage as a strong reason for excluding women from
clinical trials.
The concern for teratogenic effects is not wholly unreasonable in
light of the trauma surrounding DES.154 In fact, the FDA enacted its
rigorous standards specifying when fertile women can be included in




150. Eighty-five percent of the heads of NIH institutes are men. 1991 Federal Staff Direc-
tory (Staff Directory Ltd., 1991). Fourteen of the 14 members of the House Appropriation Sub-
committee on Labor, Health, Human Services, and Education are men. 1991 Congressional Staff
Directory (Staff Directory Ltd., 1991). Sixty-eight percent of pharmacists and 73% of medical re-
searchers are men, as are 82% of all physicians. Bureau of the Census, Statistical Abstract at 395
(cited in note 97).
151. Council on Ethical and Judicial Affairs, 266 JAMA at 559 (cited in note 5).
152. Thalidomide, a drug commonly used in Europe to prevent miscarriages, caused severe
birth defects, such as truncated and malformed limbs. So many children with such defects were
born to mothers who had taken Thalidomide that they were collectively referred to as
"Thalidomide babies."
153. Ilene Barth, Kids at Risk From Dad's Toxic Taint, Newsday 66 (April 1, 1991) (quoting
Dr. Wendy Chavkin of Beth Israel Hospital and Columbia University, arguing that "[t]he bias is
that it's the mother's drug use or infectious disease prior to pregnancy, not the father's, that was
the problem").
154. See notes 85-93 and accompanying text.
1992] 895
VANDERBILT LAW REVIEW
women and its disastrous results. However, addressing the horrific re-
sults of inadequate DES testing by making it more difficult to test fer-
tile women is problematic. This reasoning is antithetical to the FDA's
purpose since the damage caused by untested drugs could be equally as
harmful to fertile women, if not more so, than the damage caused by
controlled clinical trials. 155 Since clinical trials exist to give researchers
and developers of pharmaceutical products an opportunity to ascertain
the negative side effects of products they market, the justification of
teratogenic liability is an irreconcilable antinomy.
Additionally, since recent medical evidence indicates that many
birth defects actually may be a result of sperm damage, 56 the constitu-
tionality of the FDA's regulations regarding the testing of fertile women
is questionable under the equal protection clause. 57 If the FDA is mak-
ing its testing determinations on the basis of gender, then it will have to
justify its policy under the intermediate standard of scrutiny that
courts apply to gender based classifications.'58
1. Johnson Controls-A New Era in Equal Protection or a Holding
Limited to Title VII?
A recent Supreme Court decision, International Union v. Johnson
Controls, Inc. 59 discussed the interaction of Title VII of the Civil
Rights Act of 1964 and the Pregnancy Discrimination Act and high-
lighted the nature of gender discrimination in the workplace. Although
Johnson Controls is firmly grounded in statutory interpretation, a
broader principle-one that regards discrimination on the basis of fer-
tility as impermissible in a variety of contexts-arguably underlies the
decision.
160
155. Cotton, 263 JAMA at 1050 (cited in note 4) (quoting Dr. Sidney Wolfe of the Public
Citizens' Health Research Group, Washington D.C., arguing that " '[i]t makes sense. . . to include
a proper portion of groups who will use a drug in studies of that drug").
156. See notes 224-30 and accompanying text.
157. The Supreme Court of the United States has applied the equal protection clause to the
federal government through the due process clause of the Fifth Amendment. See, for example,
Bolling v. Sharpe, 347 U.S. 497 (1954); John E. Nowak and Ronald D. Rotunda, Constitutional
Law at 569 (West, 4th ed. 1991).
158. See Craig v. Boren, 429 U.S. 190 (1976). Additionally, the actions of pharmaceutical
manufacturers might rise to the level of state action. The state action doctrine applies to the fed-
eral government when federally protected constitutional rights are at stake. If a sufficient nexus
exists between the drug companies' actions and the actions of the FDA, then drug manufacturers
could be held as state actors acting in violation of the Equal Protection Clause. The nexus might
exist if the FDA regulations encourage, as many commentators argue they do, drug companies to
exclude women. A full discussion of the state action issue is beyond the scope of this Note.
159. 111 S. Ct. 1196 (1991).
160. When the Court decided Johnson Controls, the case was hailed as the "strongest and
most important sex-discrimination victory in nearly 30 years." Marcia Coyle, Fetal-Protection
Ruling Buoys Rights Groups, Nat'l L. J. 5 (April 1, 1991). Additionally, many commentators
[Vol. 45:877896
WOMEN IN CLINICAL TRIALS
In Johnson Controls the United States Supreme Court held that
under Title VII's bona fide occupational qualification exception161 and
provisions relating to pregnancy discrimination,6 2 an employer may not
discriminate against women with regard to job assignments on the basis
of a woman's reproductive health.163 By barring fertile women from jobs
that could potentially harm their reproductive health, while ignoring
that many of the same health hazards applied to males, the employer
based its policy on gender.6 4 The employer failed to establish that a
bona fide occupational qualification which justified the exclusion of fer-
tile women from lead-related jobs existed.'6 5 Since no bona fide reason
existed for excluding women, the policy was discriminatory, and the
Court held it impermissible under Title VII.
66
The reasoning of Johnson Controls can be analogized to the
clinical setting. As compelling as the concern for teratogenic liability
may seem in the medical context, it fails to recognize that males also
can have their reproductive health damaged by clinical trials.'67 Dam-
age to sperm potentially can be passed on to offspring in the form of
birth defects.'6 8 Although it may be far easier to conceptualize women
as the source of teratogenic effects because pregnancy is an obvious
contact point for the passage of defects to offspring, evidence increas-
ingly points to the male role in the reproductive equation as the situs of
many ill effects. 6 9 There is now evidence that many toxins actually
bind to sperm and cause birth defects in the children of men exposed to
them. 70 While some toxins cycle through the male system relatively
viewed it as an expansion of substantive rights for women at a time when procedural rights in
employment discrimination are shrinking. Id.
Some courts have begun to extrapolate from the holding in Johnson Controls that the possi-
bility of tort liability is not a sufficient interest to justify what would otherwise be considered a
constitutional violation. See, for example, Flores by Galves-Maldonado v. Meese, 942 F.2d 1352,
1364 (9th Cir. 1991) (stating that in the context of the Immigration and Naturalization Service's
detention of an illegal alien's children, Johnson Controls stands for the proposition that avoiding
lawsuits or possible tort liability does not justify a policy that violates the rights of individuals).
161. 42 U.S.C. § 2000e-2(e) (1988). This section permits some discriminatory employment
practices when the practices are related to "a bona fide occupation reasonably necessary to the
normal operation of that particular business or enterprise." Id.
162. 42 U.S.C. § 2000e(k).
163. Johnson Controls, 111 S. Ct. at 1203.
164. Id.
165. Id. at 1204-07. Lead has been shown to have a deleterious effect on the reproductive
health of both men and women exposed to it in the course of their employment.
166. Id. at 1203. The Court's decision was especially appropriate in light of evidence that
men often suffered the same reproductive ill effects as women.
167. See note 170 and accompanying text.
168. See notes 224-30 and accompanying text.
169. See notes 170-71 and accompanying text.
170. See Ricardo Yazigi, Randall Odem, and Kenneth Polakoski, Demonstration of Specific
Binding of Cocaine to Human Spermatozoa, 266 JAMA 1956 (1991). See generally, Cohen, 21
1992]
VANDERBILT LAW REVIEW
quickly, other substances, such as radioactive elements, affect male re-




If the Food and Drug Administration truly is concerned with
preventing damage to reproductive health during clinical trials, it
should be concerned that the men on whom drugs are tested could suf-
fer some sort of deleterious effect to their reproductive systems. Such
an effect might be passed on to the male subjects' offspring in the form
of birth defects or might cause spontaneous abortions in their spouses.
When the FDA allows pharmaceutical companies to test drugs that may
damage men's reproductive health, while citing reproductive health as
the reason for excluding women from the same tests, then the FDA has
based its decision on gender rather than on health concerns. The
grounds upon which the FDA bases its reasoning are, therefore, similar
to those successfully challenged in Johnson Controls.
As evidenced by its continued vitality, the concern for teratogenic
liability has strong appeal. Nonetheless, many of the same logical flaws
that existed in the employment context in Johnson Controls exist in
the drug testing context as well. First, as the Court recognized in John-
son Controls, under the Pregnancy Discrimination Act women have the
right not to be discriminated against in the job arena. 2 The Court also
stated that women may place their future offspring at risk in perform-
ing their jobs.1 3 Although the statute at issue in Johnson Controls spe-
cifically addressed employment discrimination on the basis of gender,
the underlying rationale also extends to the area of drug testing. As in
Johnson Controls, the rationale for excluding women on the basis of
their ability to bear children does not hold up to careful scrutiny since
many of the same health concerns apply to men as well.
Johnson Controls may signal that discrimination in contexts other
than employment also is impermissible. Its language implies that repro-
ductive capacity is an impermissible basis for discrimination, particu-
larly when the same potential damage faces both males and females.17 4
Johnson Controls also implies that potential damage to unborn chil-
dren is not a sufficient rationale for discriminating against women. 5
Some might argue that the Court's earlier holding in Geduldig v.
Aiello176 forecloses this line of argument. The insurance policy at issue
Nursing Clinics of N. Am. at 49 (cited in note 24).
171. See Cohen, 21 Nursing Clinics of N. Am. at 61.62 (cited in note 24).
172. 111 S. Ct. at 1203 (citing 42 U.S.C. § 2000e(k)).
173. Id. at 1210.
174. Id. at 1203.
175. Id. at 1210.
176. 417 U.S. 484 (1974) (holding that discrimination on the basis of pregnancy is not gender
discrimination for the purposes of the Equal Protection Clause).
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in Geduldig, however, discrimated on the basis of pregnancy. The Court
stated that a classification based on pregnancy, which by its nature only
affects women, did not constitute gender discrimination because the
other group included in the policy's rubric, nonpregnant persons, by
definition included men and nonpregnant women. '77 Unlike the insur-
ance policy in Geduldig, the FDA guidelines discriminate on the basis
of the capacity to become pregnant, a classification that includes a far
broader number of women than were covered in Geduldig. In fact, the
exclusionary policy at issue in Johnson Controls considered all women
under the age of 70 to be fertile unless otherwise documented.
17
In general, Geduldig has been a highly criticized case.179 Over two
dozen law review articles and several other analyses of constitutional
doctrine agree that the case was wrongly decided.8 0 Even the principal
scholarly defense of the case agrees that the Court erred in determining
that discrimination on the basis of pregnancy was not gender discrimi-
nation."' The Court itself has rarely cited the decision.' 2 In Turner v.
177. Id. at 496-97 & n.20.
178. Johnson Controls, 111 S. Ct. at 1200. Interestingly, the argument that there is a distinc-
tion between classifications on the basis of pregnancy and those on the basis of capacity to become
pregnant was raised in oral argument before the Court in Bray v. Alexandria Women's Health
Clinic No. 90-985 reported in Abortion-Ban on Obstructing Access to Clinics-42 U.S.C. 1985(3),
60 U.S.L.W. 3331 (Nov. 5, 1991). The federal government argued before the Court that the class at
issue in Johnson Controls was fertile women, and that the Court should not overrule Geduldig's
logic, because both classes at issue in Bray, those involved in the abortion process and those not
involved, included both women and men. Id. at 3332. The government saw no tension between
Johnson Controls and Geduldig because the former was gender discrimination based on fertility
while the latter, as in Bray, dealt with no gender classification since the protected class included
both women and men. Id. Counsel also argued that the discrimination in Johnson Controls was
distinguishable because it was against women generally. Id. In effect, the policies of excluding fer-
tile women from clinical trials excludes so many women that it is more like discrimination on the
basis of gender than on the basis of pregnancy.
179. In her law review article, Equality's Riddle: Pregnancy and the Equal Treatment/Spe-
cial Treatment Debate, 13 N.Y.U. Rev. L. & Soc. Change 325 (1985), Professor Wendy Williams
argued that pregnancy and lactation were the only criteria that separated women from men. Pro-
fessor Ann Scales similarly argued:
In observing that these are the capabilities which really differentiate women from men, it is
crucial that we overcome any aversion to describing these functions as "unique." Uniqueness
is a "trap" only in terms of an analysis, such as that generated in Geduldig v. Aiello, which
assumes that maleness is the norm. "Unique" does not mean uniquely handicapped.
Ann Scales, Towards a Feminist Jurisprudence, 56 Ind. L. J. 375, 435 (1981).
180. See, for example, Nancy Erickson, Equality Between the Sexes in the 1980's; 28 Cleve.
St. L. Rev. 591 (1979); Ruth Bader Ginsberg, Gender in the Supreme Court; The 1973 and 1974
Terms, 1975 Sup. Ct. Rev. 1; Laurence Tribe, American Constitutional Law § 16-29 (Foundation,
2d ed. 1988).
181. Law, 132 U. Pa. L. Rev. at 984 (cited in note 40) (citations omitted). The defenders of
Geduldig believe that the classification could have been upheld as reasonable. See, for example,
Stanley Schair, Sex Discrimination: The Pregnancy-Related Disability Exclusion, 49 St. John's L.
Rev. 684 (1975).
182. The Court has cited the decision a total of 11 times as of February 1992. One case cited
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Department of Employment Security'83 the Court limited Geduldig's
holding to insurance claims. The Court subsequently expanded the
Geduldig rationale to the Title VII arena in General Electric Co. v. Gil-
bert,'8 4 but Congress quickly overruled the latter decision with the pas-
sage of the pregnancy discrimination provision of Title VII.'8 5 Since
that time, the Court has cited Geduldig only in historical recounts of
the purposes of this provision. 8 '
Professor Sylvia Law has noted that Geduldig made it doctrinally
more difficult to claim that reproductive freedom is an aspect of sex-
based equality.'8 7 However, she made this argument in 1984, long
before the Court's decision in Johnson Controls. Although Geduldig
may still have viability to the extent that pregnancy itself may not be
considered gender discrimination, the language in Johnson Controls in-
dicates that the Court perceives pregnancy as unique to women, but
does not see it as a condition universally descriptive of women.'88 The
employer's policy in Johnson Controls excluded women because they
were fertile, not because they were actually pregnant. 8 9 This language
seems to extend beyond the statutory mandate of the pregnancy dis-
crimination provision of Title VII, since under this statute even dis-
crimination on the basis of pregnancy is impermissible unless justifiable
as a bona fide occupational qualification. Therefore, the Court's distinc-
tion between fertility and pregnancy is unnecessary unless the Court is
aiming towards a broader interpretation of the Johnson Controls
holding.
In sum, the FDA has no compelling reason for preventing women
from participating in clinical trials and is engaging in impermissible
gender discrimination. In the employment context of Johnson Controls,
the Court's primary concern was to safeguard a woman's right to equal
employment as protected by Title VII.' 9° In the context of clinical tri-
als, the exclusion of women goes beyond simply the right of women to
participate in those trials on a level equal to that of men. The exclusion
goes to the fundamental purpose of the clinical trials themselves-to
it for the benign proposition that the Supreme Court need not decide if sex is a suspect classifica-
tion. Stanton v. Stanton, 421 U.S. 7, 13 (1975). Other cases cited it for general equal protection
arguments regarding insurance programs. See, for example, California Says. & Loan Ass'n v.
Guerra, 479 U.S. 272, 277 n.5 (1987).
183. 423 U.S. 44, 45 (1975).
184. 429 U.S. 125 (1976).
185. 42 U.S.C. § 2000e(k) (1988).
186. See, for example, Guerra, 479 U.S. at 277 n.5.
187. Law, 132 U. Pa. L. Rev. at 985 (cited in note 40).
188. Johnson Controls, 111 S. Ct. at 1199.
189. Id. at 1203.
190. Id. at 1210.
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insure that the drugs marketed are safe for those taking them. At least
one spokesman at the FDA also has come to the conclusion that John-
son Controls mandates that women, and not the FDA, are to make the
determination of how best to protect the fetus.19'
2. The FDA's Guidelines for Testing Fertile Women: Do They Pass
Equal Protection Requirements?
In its regulation of human clinical trials, the FDA issues policy
statements designed to guide both FDA administrators in approving
permissible clinical trials and researchers in developing those trials.'
92
In its policy statement, "General Considerations for the Clinical Evalu-
ation of Drugs" (the Guidelines), the FDA sets forth the circumstances
under which clinical trials of fertile women will be permissible. 93 The
FDA Guidelines provide that a woman of childbearing potential'
94
should be excluded from the earliest dose-ranging studies.1 95 The FDA
Guidelines further state that such women also should be excluded from
the second phase of clinical trials. 96 Large scale clinical trials may be
initiated with women of childbearing potential only at the last stage of
clinical testing,1 97 and then only if sufficient information regarding the
efficacy and relative safety of a drug has been accumulated and ade-
quate reproduction studies have been completed in animals.1
9 8
The FDA allows only two exceptions to this procedure. First, in
studies testing drugs that have teratogenic potential but also have a
life-saving or a life-prolonging quality, women who have been institu-
tionalized for a period of time adequate to establish a nonpregnant
191. Telephone interview with Dr. Robert Temple (cited in note 43).
192. See, for example, FDA Guidelines (cited in note 39).
193. Id. at 10-11.
194. A woman of childbearing potential is defined as a premenopausal female capable of be-
coming pregnant, including women on oral contraceptives and women in mental institutions, but
not including women in prisons. Id. at 10.
195. During this phase, investigators administer the new drug to healthy volunteers to deter-
mine the metabolic and pharmacological effects. This study usually takes one to two years to com-
plete and uses between twenty and eighty subjects. Myron L. Marlin, Treatment INDs: A Faster
Route to Drug Approval? 39 Am. U. L. Rev. 171, 180 (1989). These subjects are all males or
postmenopausal females. Telephone interview with Dr. Robert Temple (cited in note 43).
196. FDA Guidelines at 10 (cited in note 39). Phase II studies, from which fertile women also
are excluded, are controlled clinical studies to determine the efficacy of the drug and to ascertain
the short term side effects and risks of the drug. These studies are closely monitored, involve
several hundred subjects, and take one to two years to complete. Marlin, 39 Am. U. L. Rev. at 180
(cited in note 195).
197. The Phase III studies are expanded trials. After the evidence is accumulated from
Phase I and II studies, Phase III studies allow researchers to gather additional information to
evaluate the drug's overall risks and benefits. Marlin, 39 Am. U. L. Rev. at 181 (cited in note 195).
198. FDA Guildelines at 10 (cited in note 39).
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state can be included.19 Second, when the disease is life-threatening,
but the teratogenic potential has not been established by animal stud-
ies, a fertile woman can be included in a clinical trial if she meets cer-
tain requirements. First, a fertile woman must take a pregnancy test;
second, she must give her fully informed consent, after the researchers
point out the lack of animal studies, and third, she must receive advice
about contraceptive measures. 0 The FDA also requires a follow-up
procedure to monitor fertile women who have had drugs administered
to them under either of these exceptions because a presumption exists
that the drugs will be transmitted through the transplacental passage
and in milk secretions. 0 1
By contrast, the FDA allows for the inclusion of fertile male sub-
jects in clinical trials unless research in laboratory animals has uncov-
ered abnormalities in the testes or in spermatogenesis.0 2 Even if such
abnormalities are detected, males still can be included in all phases of
clinical trials depending on the nature of the disease, the importance of
the drug, the duration of drug administration, and the dosage at which
the abnormality occurred.20 3
The purpose of the Guidelines is to protect the fetus from terato-
genic damage by limiting the participation of potential mothers in
clinical trials. 4 In light of this goal, the FDA Guidelines are both un-
derinclusive and overinclusive. They are underinclusive because they al-
low women in prisons to be included in clinical trials regardless of their
childbearing potential20 5 despite the fact that women in prison can be-
come pregnant, if not while in prison, then certainly upon release. Addi-
tionally, they regularly include fertile males although testing may cause
damage to the male reproductive system and cause birth defects and
miscarriages as well.20 6 The FDA Guidelines are overinclusive because
they include many women who do not have the potential to become
pregnant. For example, the FDA Guidelines do not permit testing on
women using oral contraceptives, regardless of the minimal chance of
pregnancy.20 7 According to an FDA spokesman, the FDA is aware of
199. Id.
200. Id. at 10-11. In practice the latter exception has not resulted in the inclusion of women
in important life-saving research. For example, the Centers for Disease Control recently advised
against giving certain investigational treatments for Acquired Immune Deficiency Syndrome to
pregnant women despite the life-threatening nature of the disease. Chavkin and Fox, 264 JAMA at
974 (cited in note 3).
201. FDA Guidelines at 11 (cited in note 39).
202. Id. Spermatogenesis is the creation of sperm.
203. Id.
204. Chavkin and Fox, 264 JAMA at 973 (cited in note 3).
205. FDA Guidelines at 10 (cited in note 39).
206. See notes 224-30 and accompanying text.
207. See FDA Guidelines at 10 (cited in note 39). If birth control pills are taken according to
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these anomalies and currently has plans to alter its Guidelines later this
year.208 The new Guidelines will take into account a woman's actual po-
tential for becoming pregnant, including whether she is using
contraceptives.°s
Even if the FDA corrects these anomolies, however, the Guidelines
arguably still would constitute an impermissible gender classification.
First, although the Supreme Court has upheld pregnancy-based distinc-
tions in Geduldig v. Aiello,21 0 the Guidelines distinguish between those
with the capacity to become pregnant, by definition only fertile women,
and those without the capacity to become pregnant, a category that also
includes postmenopausal women and, apparently, women in prison.21'
Since the Guidelines do not exclude only women who are actually preg-
nant, they more clearly resemble the employment policy struck down in
Johnson Controls 12 than the disability benefits law at issue in
Geduldig.2"3 As the Supreme Court implicitly recognized in Johnson
Controls, discrimination on the basis of the ability to become pregnant
is a gender classification.214
If the FDA Guidelines are based upon a gender classification, this
classification must meet the requirements of the equal protection
clause. Here, the standard the Supreme Court set forth in Craig v. Bo-
ren, 2 5 intermediate level scrutiny, would apply. Therefore, in order for
the classification to be constitutionally permissible, the government
must show an important governmental objective and the government's
means must be substantially related to this objective.216 Certainly the
FDA has an important governmental interest in protecting the repro-
ductive health of women in clinical trials and in protecting the future
offspring of those women from birth defects. Whether the means the
FDA has chosen are substantially related to this interest, however, is
another matter.
First, by protecting only some fertile women from the dangers of
clinical trials and not protecting others, the FDA fails to tailor its
their directions-one a day without missing any pills-they are about 99% effective. Robert
Berkow, ed., The Merck Manual of Diagnosis and Therapy 1732 (Merck, Sharp and Dohme Re-
search Laboratories, 15th ed. 1987). The actual failure rate for birth controls pills experienced by
all couples taking them is 3%. Physicians Desk Reference 2485 (Medical Economics Data, 46th ed.
1992) (listing data on the Norplant system of birth control).
208. Telephone interview with Dr. Robert Temple (cited in note 43).
209. Id.
210. 417 U.S. 484 (1974).
211. See FDA Guidelines at 10 (cited in note 39).
212. Ill S. Ct. 1196 (1991).
213. 417 U.S. 484.
214. 111 S. Ct. at 1203.




means sufficiently to its end of preventing future birth defects. For ex-
ample, a female prisoner who participated in a clinical trial, became
pregnant, and had a child with a birth defect would not be protected
under the current FDA Guidelines, nor would a child whose father suf-
fered harm to his reproductive capacity.
Second, since the difficulty of including fertile women in clinical
trials has resulted in their exclusion from most clinical research alto-
gether,217 the FDA allows the release of drugs on the market with little
or no understanding of their effects on women or of their potential ef-
fects on future offspring. If the goal is to protect future offspring from
birth defects, then the government could require teratogenic animal
studies, such as those now required before fertile women are included,
and other studies to determine the teratogenic potential of the drugs. 18
Once these tests are run, the tested drugs could be marketed, as they
often are now, with a statement that there is no evidence of teratogenic
effects of the substance but that, since the drug has not been tested on
pregnant women, it should not be used during pregnancy. 19
The exclusion of fertile women does little to effectuate the end of
preventing teratogenic effects; pregnant women cannot under any cir-
cumstances be tested, so only women who are not currently pregnant
would be involved. Therefore, fertile women who are informed of the
potential risk and who use some form of contraception could be fol-
lowed after the clinical trials to determine if there are any long term ill
effects of the drug. The exclusion of such women from clinical trials
does little to enhance the goal of fetal protection in the light of increas-
ingly effective contraceptive measures. The current practice of releasing
a drug with an incomplete understanding of its impact on the female
physiology thus seems counterintuitive.
Third, if the goal is to protect women and future children from
damage, then the exclusion of fertile women from the dose-ranging and
other early phases of clinical trials does not achieve this end. According
to one spokesman, the FDA believes that no scientific reason exists to
mandate the inclusion of women in the early phases of clinical trials.1
20
Nonetheless, the spokesman concedes that there may be unknown dif-
217. See, for example, Cotton, 263 JAMA at 1050 (cited in note 4); Hamilton and Parry, J.
Am. Med. Women's Ass'n at 130 (cited in note 2).
218. Gilden and Bodewitz, 32 Soc. Sci. & Med. at 1194-95 (cited in note 24).
219. See, for example, Physicians Desk Reference 920 (cited in note 207) (listing precautions
for Prozac, and stating that although there is no evidence of teratogenic potential based on animal
studies, and ethical considerations prevent the testing of pregnant women, consumption of Prozac
during pregnancy is not recommended).
220. Telephone interview with Dr. Robert Temple (cited in note 43). Dr. Temple stated that
although there is no compelling medical reason to include women in the early phases of clinical
trials, there may be personal liberty interests involved.
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ferences in proper dose levels between males and females that have not
been studied.22 ' Research following the release of many antidepressant
drugs, for example, has shown that doses proper for males are not
proper for, and are possibly even dangerous to females. Effective doses
for women can be determined through careful dose-ranging studies per-
formed after teratogenic trials have been run on animals. Manufactur-
ers then would be certain that the dosages were as low as possible, yet
still effective, and that the dose levels were safe for those taking
them.222
Finally, if the government's goal is to protect future offspring, the
FDA Guidelines, which carefully protect fertile women yet allow fertile
men to be tested unless there is a strong risk of damage to the male
reproductive system,223 are grossly underinclusive. Recent studies show
that sperm can carry substances into the female reproductive tract and
may cause birth defects in offspring. 2 4 Malformations or behavioral ab-
normalities in offspring, and even spontaneous abortions, 25 can result
when a damaged sperm fertilizes an egg. A severely damaged sperm also
can cause a type of infertility that is difficult to detect.226 Although the
medical information is still preliminary and uncertain,227 it strongly
suggests that many of the seventy-five percent of birth defects previ-
221. Id.
222. Investigators detect and reject nearly all drugs subsequently deemed unsafe during
Phase II of the clincial trials. Marlin, 39 Am. U. L. Rev. at 180 (cited in note 195).
223. FDA Guidelines at 11 (cited in note 39).
224. Dwight E.M. Angell, Sperm Damage Linked to Birth Defects, Gannett News Service
(available in Nexis library, Wires file) (Dec. 31, 1991). This cocaine bonding has been linked to
abnormal development in the offspring of cocaine fathers. Yazigi, Odem, and Polakoski, 266 JAMA
at 1956 (cited in note 170).
Exposure to chemicals in the workplace can also damage sperm. Lead has been linked to ad-
verse effects on both male and female reproductive systems and appears to have a direct effect on
the male gonads. It alters spermatogenesis and leads to increased sperm abnormalities, decreased
fertility in men, and an increased abortion rate in the wives of men exposed. Cohen, 21 Nursing
Clinics of N. Am. at 59 (cited in note 24). Additionally, anesthetic gases have been shown to affect
the male system negatively. A large study of 49,585 operating room personnel and a control group
of 23,911 health professionals showed a statistically significant increase in spontaneous abortions
in the wives and congenital abnormalities in the infants of the male physicians exposed to anes-
thetics. An increased rate of spontaneous abortion also exists in the wives of dentists. Id.
For an interesting case study of work-related reproductive abnormalities, see Andrew F. 01-
shan, Kay Teschke, and Patricia A. Baird, Birth Defects Among Offspring of Firemen, 131 Am. J.
of Epidemiology 312 (1990). See also Anne Merewood, Father Figures-Men Bear Responsibility
in Producing Healthy Babies, Chicago Trib. 5 (Sept. 29, 1991).
225. See sources cited in note 224.
226. Anne Merewood, Sperm Under Siege: More Than We Ever Guessed, Having a Healthy
Baby May Depend on Dad, Health 53 (April 1991).
227. Id. Medical information surrounding the contribution of toxins to male reproductive
damage is sketchy because relatively few well-designed and careful studies have been conducted.
See Leading Work-Related Diseases and Injuries-United States, 254 JAMA 1891, 1892 (1985).
See also Cohen, 21 Nursing Clinics of N. Am. at 49 (cited in note 24).
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ously attributed to obscure causes 228 could be linked to the father.
Some studies, for example, suggest that cocaine bonds to sperm. These
studies further conclude that many different types of environmental
and chemical factors could result in sperm damage and birth defects. 229
As medical researchers uncover the paternal contribution to fetal dam-
age, they should move away from the assumption, apparent in the cur-
rent FDA regulations, that only the mother's fetal environment is
important.230 If the Guidelines exist to protect fetal health by protect-
ing the maternal environment, then they are not sufficiently related to
that end. A fertile woman who is unable to participate in a clinical drug
trial could become pregnant by a man who was included in the trial and
still could suffer a miscarriage, or bear a child with a birth defect as a
result of testing.
The FDA Guidelines could be viewed as gender neutral in the sense
that the class of people allowed into clinical trials does include women,
although not fertile ones. 23' If so, then the constitutional question be-
comes whether the government's ends bear a rational relationship to a
permissible government goal. 232 Yet, even under the rational basis test,
the FDA standard fails to pass muster. Although the goal of protecting
future children from unnecessary injury is a permissible one, excluding
fertile women from clinical trials is not a rational way to accomplish
this end. Since the purpose of the clinical trials is to determine the neg-
ative side effects of drugs, and teratogenic environments are negative
side effects, removing fertile women from the earliest stages of clinical
investigation, when researchers determine most of the negative aspects
228. Ilene Barth, Kids at Risk From Dad's Toxic Taint, Newsday 66 (April 1, 1991).
229. Many chemicals, such as dibromochloropropane (a soil fumigant), carbon disulfide (used
in dry cleaning), oral contraceptives during manufacture, and ethylene dibromide (a fumigant and
component of leaded gasoline) have all been linked to sperm damage and adverse reproductive
results. Cohen, 21 Nursing Clinics of N. Am. at 60-61 (cited in note 24).
Additionally, physical agents, such as heat and radiation, have been shown not only to cause
adverse reproductive outcomes, but also to continue to adversely affect male reproduction and
fetal development for a long time after paternal exposure. Radiation presents an especially perni-
cious result since it can be the cause of spontaneous mutations in offspring of exposed males many
generations later. Id. at 62. The occurrence of certain sporadic mutations in the offspring of older
fathers has been well-established. Id.
Men with low vitamin C levels are more apt to have genetically damaged sperm, as are men
who smoke, drink alcohol or use illicit drugs. Eleven or more X-rays before conception can lead to
chromosomal damage in men. Angell, Gannett News Service (cited in note 224).
230. See Jane Brody, Personal Health, N.Y. Times 64 (Dec. 25, 1991). See also Cohen, 21
Nursing Clinics of N. Am. at 62 (cited in note 24) (arguing that "[t]he question of whether or not
teratogens can act through the male is complex.. . . Yet, we must remember that it was not long
ago that the placenta was assumed to be an impenetrable barrier between mother and fetus. This
field is ripe for further well-designed and careful investigation.")
231. See Geduldig v. Aiello, 417 U.S. 484 (1974).
232. Id.
[Vol. 45:877
WOMEN IN CLINICAL TRIALS
of drugs,233 means that many drugs are released for use by fertile
women without an understanding of the potential effects on those
women. The exclusion of fertile women does little to increase the safety
of their future children and, in fact, may lead to another DES-type cri-
sis.234 The best way to protect future offspring, then, is to determine
early in the clinical testing process whether there will be a teratogenic
effect either from the mother or the father, a result that is not achieved
when women are excluded from drug trials altogether.
B. Liability of Drug Manufacturers
The pharmaceutical houses apparently have made a kind of cost-
benefit analysis-weighing the cost of including fertile women in
clinical trials or possibly having to run trials twice, once on men and
once on women, versus the liability for releasing a relatively untested
drug-and have decided that the former would be more costly than the
latter. However, the pharmaceutical companies bankrupted as a result
of the DES crisis, a classic example of teratogenic liability on a grand
scale, 35 probably would disagree with this conclusion.
1. Liability for Damage During Clinical Trials
Although human participants in clinical trials sign detailed and
thorough informed consent forms,236 pharmaceutical companies and re-
searchers still fear that should a fertile woman participate in a test and
suffer some damage to her reproductive health, a consent form would
not protect them from liability. 37 Informed consent forms have been
struck down by courts as invalid in other contexts. 238 To date, however,
apparently no suit has been brought against a pharmaceutical house for
damage caused during a clinical trial.
The federal government requires that researchers obtain the in-
formed consent of participants before they proceed with clinical trials.
The specific content of the informed consent also is regulated by the
government. 39 All research supported by federal funds must comply
with these informed consent standards, which include a description of
233. See Marlin, 39 Am. U. L. Rev. at 180 (cited in note 195). Additional studies have linked
the use of tobacco and alcohol by fathers to sperm damage, birth defects and a whole host of
childhood diseases.
234. Saunders and Saunders, 11 Health Care for Women Int'l at 424-25 (cited in note 24).
235. See id. at 423-25, 429-30.
236. See FDA Guidelines at 2 (cited in note 39).
237. Chavkin and Fox, 264 JAMA at 973 (cited in note 3).
238. For example, a doctor cannot force his patient to sign a consent form absolving the
doctor of liability for negligence.
239. 45 C.F.R. § 46.116 (1991) (setting forth general requirements for informed consent).
1992]
VANDERBILT LAW REVIEW
any reasonably foreseeable risks or discomforts, a description of any
benefits the subject will receive, and a statement that participation is
completely voluntary and can be discontinued at any time.240 The regu-
lations further provide that if the research involves more than minimal
risk, an explanation as to whether any compensation or treatments for
injury will be available must be given to the subject.241 Despite these
regulations, researchers fear that a court faced with a child suffering
from a birth defect would find these standard consent forms invalid
with little hesitation.242
Some members of the medical profession take exception to this as-
sumption.243 They argue that the concern for liability, despite the exis-
tence of consent forms, is based on the assumption that an adult
woman is not competent to make an informed decision regarding her
participation in a clinical trial, in spite of a process by which she is
made to understand the risks and benefits to her own health and possi-
ble risks to an embryo.244 These medical professionals also refute the
assumption that, if a woman in a clinical trial suffers a contraceptive
failure, she could not make a responsible and intelligent determination
whether or not to terminate the pregnancy or carry the fetus to term.2 45
Presumably, private pharmaceutical companies fear tort liability if she
continues the pregnancy and gives birth to a damaged child. This con-
cern, however, should be minimized if honest and thorough informed
consent procedures are followed.246 The government may fear that the
woman will decide to abort the fetus. Commentators believe that the
government prefers to avoid all situations in which the abortion contro-
versy may arise.2 47 In sum, the decision to exclude fertile women from
clinical trials is an example of legal and political considerations "unduly
influencing" health and research policy decisions. 48
Another, more valid, concern on the part of drug manufacturers is
not that the woman herself would bring suit, but that her child would
bring suit as a result of birth defects. The general rule is that parents
cannot waive causes of action on behalf of their children,249 and virtu-
240. Id. §§ 46.116(a)(2)-(3), (8).
241. Id. § 46.116(a)(6).
242. Dr. Temple of the FDA stated that anyone who knew anything about the courts in this
country would know the consent forms were not worth anything should a birth defect actually
occur. Telephone interview with Dr. Robert Temple (cited in note 43).
243. See, for example, Chavkin and Fox, 264 JAMA at 973-74 (cited in note 3).
244. Id. at 973.
245. Id.
246. Id.
247. Id. at 973-74.
248. Thomas C. Chalmers, M.D., In Reply, 264 JAMA 974 (1990) (responding to Chavkin
and Fox, 264 JAMA at 973 (cited in note 3)).
249. See, for example, Johnson Controls, 111 S. Ct. at 1211 & 1211 n.3 (White concurring).
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ally all jurisdictions allow tort claims for prenatal injuries provided the
child is born alive.2 50 Nevertheless, because there are various reliable
ways of protecting against pregnancy during the course of the trial, the
concern that there would be liability as a result of damage done to a
fetus during clinical trials is' not well-founded. A woman could agree, as
part of her consent to clinical trials, that she would abstain from sexual
intercourse for the duration of the trial or that she would use the most
reliable form of birth control available to prevent pregnancy.
Norplant,2 51 for example, is a form of birth control that is ex-
tremely effective-even more effective than female sterilization. "52 Nor-
plant is used easily, and when the implant is removed, fertility returns
quickly.25 3 A woman could agree to have Norplant installed for the pe-
riod of the clinical trials and removed once the trials were completed.
Additionally, women who have been sterilized by tubal ligation254 have
the same hormonal cycles and menstruate like women who are com-
pletely fertile.255 Since one of the major problems with the failure to
test drugs on fertile women is the uncertainty regarding effects during
women's cycles, utilizing women who have been surgically sterilized, yet
who retain the hormonal structure of fertile women, would address both
the dangers of excluding fertile women and the fear of teratogenic
liability.
If the FDA were to require pharmaceutical houses to include fertile
women, or at least women with the cycles of fertile women in their
clinical trials, the drug companies could limit their legal exposure. If
the informed consent signed by a woman before a clinical trial con-
tained an agreement to use Norplant, and a failure of the system re-
sulted in injury to a child, it would be difficult for the child to argue
that the pharmaceutical companies failed to take due care to prevent
the injury. In fact, the companies would have taken the best precau-
tions available, so the chance of their being found negligent would be
250. Id. at 1210-11 (citing W. Page Keeton et al., Prosser & Keeton on the Law of Torts § 55
at 368 (West, 5th ed. 1984)).
251. The Norplant System is a group of six levonorgestrel (a progestin) implants which are
installed under a woman's skin using a local anesthetic. It can be installed in a ten to fifteen
minute office visit. It prevents contraception with a continuous dose of hormones that are released
into the body. Physicians Desk Reference at 2484-88 (cited in note 207).
252. Norplant has an expected failure rate of 0.2% during the first year of use. Its typical
failure rate (the actual failure rate experienced by users of the system) is also 0.2%. It is currently
the most effective form of birth control next to male sterilization, which has an expected failure
rate of 0.1% and a typical failure rate of 0.15%. By contrast, female sterilization has an expected
failure rate of 0.2%, but a typical failure rate of 0.4%. Id. at 2485 table 2.
253. Id. at 2485.
254. Tubal ligation is the tying of the fallopian tubes.
255. R. Rivera, et al., Menstrual Patterns and Progesterone Circulating Levels Following




If a pharmaceutical house were to require, as part of its informed
consent agreement, that those participating in its clinical trials abstain
from sexual intercourse for the duration of the study, and a woman
failed to adhere to the agreement and became pregnant, her willful con-
duct would break the chain of causation between the pharmaceutical
company and the child's injuries. At one time, a court might have
wanted to circumvent this causation principle in order to allow the
child some sort of recovery. The trend now, however, is increasingly to-
ward the elimination of parent-child immunity-meaning that an in-
jured child could sue his mother for his or her injuries.2 56 Furthermore,
genetic testing often can determine whether a fetus contains a potential
birth defect in time for an abortion should an anomaly be detected.257
At least one court has suggested that a child born with severe birth
defects could successfully sue the mother for her failure to obtain an
abortion in light of her knowledge that the child would be born
defective.2 58
Even if there is potential liability for damage caused in clinical
testing despite rigorous informed consent, such concerns pale when
compared to the risk posed by a drug that is released on the market
without sufficient testing. The nightmare that followed the administra-
tion of DES to pregnant women provides the best example of this prob-
lem.259 The FDA hopes to prevent another DES situation by requiring
all of the teratogenous studies to be completed on animals before fertile
women are included in clinical trials.260 As with many drugs not exclu-
sively for use by women, this requirement effectively operates to bar
fertile women from clinical trials.2"' Thus, the potential teratogenic ef-
256. For a discussion of the issues surrounding such suits, see Ron Beal, "Can I Sue
Mommy?": An Analysis of a Woman's Tort Liability for Prenatal Injuries to Her Child Born
Alive, 21 San Diego L. Rev. 325 (1984).
257. For a discussion of the limits on genetic screening and potential abuses in the employ-
ment context, see Larry Gostin, Genetic Discrimination: The Use of Genetically Based Diagnostic
and Prognostic Tests by Employers and Insurers, 17 Am. J. L. & Med. 109 (1991).
258. Curlender v. Bio-Science Laboratories, 106 Cal. App. 3d 811, 165 Cal. Rptr. 477, 488
(1980) (observing that there is "no sound public policy which should protect those parents from
being answerable for the pain, suffering and misery which they have wrought upon their
offspring").
The California legislature acted quickly in response to this suggestion by passing in 1981
§ 43.6 of the Civil Code, which relieves parents of any liability for not having an abortion and
provides that it is no defense in any action against a third party that an abortion could have been
obtained. Cal. Civil Code § 43.6(a)-(b) (West 1982). Additionally, the choice not to have an abor-
tion cannot be figured into a damage award. Turpin v. Sortini, 31 Cal. 3d 220, 643 P.2d 954, 182
Cal. Rptr. 337 (1982).
259. Saunders and Saunders, 11 Health Care for Women Int'l at 424-25 (cited in note 24).
260. FDA Guidelines at 10 (cited in note 39).
261. See Chavkin and Fox, 264 JAMA at 973 (cited in note 3).
910 [Vol. 45:877
WOMEN IN CLINICAL TRIALS
fects of many commonly used drugs remains unknown.
The point of clinical trials is to determine if there will be any ill
effects from the drug. Without clinical trials, many side effects remain
undetected until after the drug has been released to the general popu-
lace, as was the case with DES.2"2 The clinical trials exist to assess the
potentially damaging effects of a drug and either to rectify them when
possible or at least to warn users of the potential risks. With drugs
tested exclusively on males, pharmaceutical houses risk much greater
liability by releasing a drug on the market with an incomplete under-
standing of the potential risk to women.263 Thus, the exclusion of fertile
women from clinical trials may actually expose pharmaceutical compa-
nies to significant liability despite the ostensibly noble goal of protect-
ing women."'
2. Liability for Damage Caused by Relatively Untested Drugs
A drug manufacturer has a duty to distribute a product that is fit
for its intended purpose.6 5 The mere fact that the FDA has approved a
drug for marketing does not insulate pharmaceutical manufacturers
from liability for damage caused by that drug.266 The Supreme Court
has been reluctant to find that FDA regulations preempt state tort
law,267 and a majority of states have held that compliance with FDA
standards is insufficient to immunize the drug manufacturer from state
tort claims. 26  One of the requirements for a finding of implied preemp-
tion of state court claims is that the federal and state law interests be in
conflict.26 9 Since the goal of both the FDA regulations and state tort law
262. Saunders and Saunders, 11 Health Care for Women Int'l at 424-25 (cited at note 24).
263. See notes 49-95 and accompanying text.
264. Id.
265. See Feldman v. Lederle, 97 N.J. 429, 479 A.2d 374 (1984).
266. See, for example, Abbot v. American Cynamid, 844 F.2d 1108 (4th Cir. 1988); Hurley v.
Lederle, 851 F.2d 1536 (5th Cir. 1988). But see Grundberg v. Upjohn, 813 P.2d 89 (Utah 1991)
(holding that FDA approved prescription drugs are unavoidably dangerous in design; therefore,
manufacturers are immune from strict liability).
267. See Jones v. Rath Packing Co., 430 U.S. 519, 525 (1977) (stating that state police pow-
ers are not superseded by federal law "unless that [is] the clear and manifest purpose of
Congress").
268. See, for example, Graham v. Wyeth Laboratories, 666 F. Supp. 1483, 1493 (D. Kan.
1987) (stating that "[w]hile Congress intends vaccines to be at least as uniformly safe as the FDA
regulations require, there has never been a congressional intent that innocent victims of adverse
reactions should be precluded from being compensated"); MacDonald v. Ortho Pharmaceutical
Corp., 394 Mass. 131, 475 N.E. 2d 65 (1985) (stating that compliance with the FDA standards was
not a shield against state tort liability); Feldman, 479 A.2d at 383 (stating that regulation by the
FDA will not insulate drug manufacturers from liability).
269. Comment, Federal Preemption and the FDA: What Does Congress Want? 58 U. Cin. L.
Rev. 263, 266 (1989) (citing Hillborough County, Fla. v. Automated Medical Laboratories, 471
U.S. 707, 713 (1985)). Since the FDA regulations do not expressly preempt state tort law, the
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is to provide the consumer with safe and effective pharmaceutical prod-
ucts,27 courts view state tort actions as increasing the incentive for
drug manufacturers to improve the quality and safety of their prod-
ucts. 271 Allowing pharmaceutical manufacturers to use FDA compliance
as immunization from liability would defeat the purposes behind both
the FDA regulations and state tort law. Courts, therefore, are under-
standably reluctant to find preemption in the pharmaceutical
context.
27 2
Whether pharmaceutical manufacturers should be held to a negli-
gence or a strict liability standard has been the subject of much discus-
sion.273 Most states have adopted the Restatement Second of Torts
Section 402A's requirement of strict liability for pharmaceutical prod-
ucts.27 4 Those states which have adopted this rule often mitigate it by
the use of Comment k to the Restatement,2 75 which insulates manufac-
turers of unavoidably unsafe products from strict liability. These states,
however, do not find that Comment k insulates all drug manufacturers
courts use a three-part standard to determine if there is implied preemption: first, the comprehen-
sive nature of the federal regulations; second, the dominant federal interest in the matter regu-
lated; and third, whether there is a direct conflict between state tort law and the federal
regulations. The Supreme Court has been reluctant to find implied preemption of state claims with
a comprehensive federal statute, and is even more reluctant to do so with regard to comprehensive
federal regulation. Id.
270. MacGillivray v. Lederle Laboratories, 667 F. Supp. 743, 745 (D.N.M. 1987) (reasoning
that the object of the FDA regulations is to provide safe and effective drugs to the public and
rejecting a drug manufacturer's claim of preemption).
271. See Graham, 666 F. Supp. at 1493.
272. For a good general discussion of preemption of state court claims for defects in drugs,
see Comment, 58 U. Cin. L. Rev. at 263 (cited in note 269). See also Federick H. Fern and Lewis
Bartell, Federal Preemption of Pharmaceutical Labeling, For the Defense 20 (July 1987), for a
discussion of the history of the preemption doctrine with regard to pharmaceutical products and
an argument for more court deference to the FDA at least in the context of pharmaceutical
labeling.
273. See Richard C. Ausness, Unavoidably Unsafe Products and Strict Products Liability:
What Liability Rule Should be Applied to the Sellers of Pharmaceutical Products?, 78 Ky. L. J.
705 (1989-90); Comment, Comment k Immunity to Strict Liability: Should All Prescription Drugs
Be Protected? 26 Houston L. Rev. 707 (1989); Note, A Prescription for Applying Strict Liability:
Not All Drugs Deserve Comment k Immunization, 21 Ariz. St. L. J. 809 (1989). Section 402A
establishes strict liability for some manufacturers of unsafe products. Comment k creates an ex-
ception to this rule. Comment k provides, in part, that:
[t]here are some products which, in the present state of human knowledge, are quite incapa-
ble of being made safe for their intended and ordinary use. These are especially common in
the field of drugs. . . . The seller of such products, again with the qualification that they are
properly prepared and marketed, and proper warning is given, where the situation calls for it,
is not to be held to strict liablity.
Restatement (Second) of Torts § 402A Comment k (1965).
274. See, for example, Feldman, 479 A.2d at 381-82; Savina v. Sterling Drug, 247 Kan. 105,
795 P.2d 915 (1990). Most states have followed the rule enunciated in Feldman. Ausness, 78 Ky. L.
J. at 733 (cited in note 273).
275. See, for example, Feldman, 479 A.2d at 381-382; Grundberg, 813 P.2d 89, 92-95.
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on the basis that all their products are unavoidably unsafe.276 Those
states that use a strict liability standard for breach of warranty, but
recognize compliance with federal regulations as evidence that the
product is unavoidably unsafe, fall back on a negligence standard for
pharmaceutical products. 7
Under the strict liability standard, when the defect consists of an
improper design or warning, the reasonableness of the manufacturer in
marketing the product is a factor in determining liability.2 7 The issue
in these cases is whether the manufacturer knew of the defect in the
product and acted in a reasonably prudent manner in marketing the
product or in providing a warning.2 79 Once it is shown that the manu-
facturer knew or should have known that the drug would cause injury,
the focus is on the reasonableness of the manufacturer's conduct, much
like a negligence standard.280 The manufacturer bears the burden of
proving that its actions were reasonable in light of the expert knowl-
edge in the field.21 The manufacturer also bears the burden of proving
that it was unable to discover the defect.2"2 Finally, a manufacturer can
insulate itself from liability by giving an adequate warning.
283
Under a strict liability standard, a pharmaceutical manufacturer
could be held liable for any damage caused to females by drugs tested
solely on a male physiology. Females damaged by relatively untested
drugs can show that the manufacturer either knew or should have
known that the drug would cause injury and failed to warn of that dan-
276. See, for example, Feldman, 479 A.2d at 383. Compare cases which state that Comment k
does not apply to all pharmaceutical products, such as Hill v. Searle Laboratories, 884 F.2d 1064,
1068-69 (8th Cir. 1989); Toner v. Lederle Laboratories, 779 F.2d 1429, 1433 (9th Cir. 1986), with
cases which hold that Comment k applies to all prescription drugs, such as McElhaney v. Eli Lilly
& Co., 575 F. Supp. 228, 230-31 (D.S.D. 1983).
Courts are more willing to apply the more lenient Comment k standard than the more rigor-
ous risk-utility standard of strict liability when the risks are scientifically unknowable. Some
courts apply the Comment k standard when the risk is unavoidable in the sense that it would
entail changing the inherent nature of the product. The latter application of Comment k is the
subject of dispute in many jurisdictions, and some courts hold Comment k inapplicable if the
manufacturer did not take reasonable steps to limit the danger of the product even if that product
is useful and desirable. Ausness, 78 Ky. L. J. at 726-27 (cited in note 273) (citations omitted). It
would be difficult for a pharmaceutical company to argue that a risk to women was unknowable
when it could easily include either sterilized women or women on Norplant in its study population
and methodically study the different reactions to the product of the men and women in the study.
277. See, for example, Baldino v. Castagna, 308 Pa. Super. 506, 454 A.2d 1012, 1020 (1982);
Grundberg, 813 P.2d at 92-93.
278. See, for example, Feldman, 479 A.2d at 385-86. See generally Fern and Bartell, For the
Defense at 20 (July 1987) (cited in note 272).
279. Id.; See also Barson v. Squibb, 682 P.2d 832, 835 (Utah 1984).
280. Feldman, 479 A.2d at 385-86.
281. Id. at 386-87
282. Id.
283. See also Barson, 682 P.2d at 835.
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ger. Although pharmaceutical researchers have relied on the assumption
that the male and female physiologies are analogous, the medical com-
munity, women's organizations, and even the NIH have known for years
that this is not the case.284 If a drug was not tested for safety and effec-
tiveness on the population targeted for its use, and this failure to test
results in injury to that population, then it is inadvisable to market that
drug on a wide scale. The courts assume that pharmaceutical houses
have all the information of experts in the field.285 Because experts in
the medical field understand the dangers of marketing drugs for women
that are not tested on women, pharmaceutical manufacturers would not
meet the second requirement of the strict liability test. Their actions in
marketing these drugs simply are not reasonable. Furthermore, since it
is possible, although expensive and fraught with administrative hur-
dles,286 to run clinical tests on fertile women to determine the extent to
which the products are unsafe, pharmaceutical manufacturers cannot
claim that any drug marketed for women, but not tested on them, is
unavoidably unsafe.
Alternatively, under a negligence standard, the person injured
bears the burden of showing that the manufacturer breached a duty
which resulted in the alleged injury.28 7 Nevertheless, pharmaceutical
manufacturers are considered experts in their field, and constructive
knowledge of developments concerning their products, measured by sci-
entific literature and other means, is imputed to them.2 8 Under the
negligence standard, manufacturers have a duty to make a timely and
adequate warning either to the ultimate consumer or to a learned inter-
mediary. 8 9 If the manufacturer knew or should have known about a
danger, it still can be subject to liability even if all the government re-
quirements are met.29 °
From a negligence perspective, a pharmaceutical house that has
created and marketed a new drug for use by both genders cannot rea-
284. See notes 95-150 and accompanying text.
285. See note 281.
286. FDA Guidelines at 10-11 (cited in note 39).
287. See, for example, Baldino, 454 A.2d at 1012.
288. See, for example, Barson, 682 P.2d at 835.
289. See, for example, MacDonald v. Ortho Pharmaceutical Corp., 394 Mass. 131, 475
N.E.2d 65, 69 (1985). See generally Frederick H. Fern, The Decline and Fall of the Learned Inter-
mediary Doctrine, For the Defense 10 (Sept. 1986); Note, The Decline of the Learned Intermedi-
ary Doctrine in Favor of Direct Patient Warnings of Drug Product Risks, 43 Ark. L. Rev. 821
(1990).
Actually physicians use more prescription drugs than other medical procedures. This results in
more side effects and related injuries, however. Physicians disclose little, if any, information re-
garding the risks of these treatments. Gerald F. Tietz, Informed Consent in the Prescription Drug
Context: The Special Case, 61 Wash. L. Rev. 367, 367 (1986).
290. See Grundberg, 813 P.2d at 97-98.
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sonably argue that it is completely unaware of current medical knowl-
edge that drugs tested only on men are not always safe for use by
women. In fact, this knowledge is imputed to them.29 ' The refusal to
acknowledge that the past practices in testing and marketing drugs
have resulted in inferior health care for women is no defense to a negli-
gence claim since pharmaceutical manufacturers are under a duty to
keep abreast of current developments.292 In light of the federal govern-
ment's acknowledgement, through the NIH, that past practices in test-
ing and marketing drugs have resulted in inferior health care for
women, a manufacturer cannot reasonably argue that it was unaware of
the potential dangers to women of the drugs it markets.
Thus, under either a strict liability or a negligence standard, a
manufacturer could be liable for damage caused to females by drugs
that were tested solely on males or designed for a male physiology. The
manufacturer's compliance with FDA regulations would not be a
defense.29
3
3. Failure to Warn
A pharmaceutical house might limit or eliminate its liability by is-
suing a proper warning that a drug may not be safe for use by fertile
women. Under a negligence or strict liability standard, the manufac-
turer's failure to warn of a danger in a drug that the manufacturer
knew or should have known about subjects the manufacturer to liabil-
ity.294 Many states hold that the failure to warn of a known danger is
negligence per se, whether that knowledge was constructive or actual.295
The difficulty of a warning in the present context comes in two
forms. First, a warning's efficacy is a serious concern. To be liable for a
failure to warn, the individual injured must show that she would not
have used the drug had a proper warning been given.296 In the context
of pharmaceutical products, this argument is problematic since pharma-
ceutical products are often necessary for the treatment of illnesses and
most products used to treat serious illnesses have been tested only on
291. See Barson, 682 P.2d at 835-36.
292. Id.
293. See, for example, Malek v. Lederle, 466 N.E.2d 1038 (Ill. App. 1984).
294. See id. See also Hasler v. United States, 517 F. Supp. 1262 (E.D. Mich. 1981).
295. See, for example, Barson, 682 P.2d at 835. A drug manufacturer must warn about the
dangers of its product even if the utility of the drug outweighs the risk. It will be held strictly
liable for the failure to do so. Ausness, 78 Ky. L. J. at 716 (cited in note 273).
Pharmaceutical manufacturers are required to warn even if the risk affects only a small pro-
portion of the products' users. Id. at 717. Women are the primary users of pharmaceutical products
so they should be entitled to a warning that the drugs they are using might not be safe.
296. See, for example, MacDonald, 475 N.E.2d at 72.
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men.2 97 The presence or absence of such a warning might not make any
difference to a woman's choice.
Second, when the manufacturer warns that a drug is not safe for
use by over one-half of the population,29 a pharmaceutical company's
financial interests are seriously implicated. Such a warning would not
be in a company's best interests regardless of the limitation it might
place on its liability. Not only would this type of warning have serious
and frightening consequences for women's health care, it would be eco-
nomically disadvantageous for pharmaceutical houses.299 On the other
hand, this seemingly impossible conundrum for pharmaceutical
houses-warn and suffer the economic consequences or fail to warn and
be subject to liability-could be the very impetus needed to encourage
manufacturers to begin to include women in their clinical trials.
V. SOLUTIONS
A. Administrative Solutions
1. Lighting a Fire Under the NIH
One possible course of action for those who criticize the NIH's fail-
ure to enforce its own policy regarding the inclusion of women in
clinical trials is to push the agency toward enforcement. Although en-
forcement decisions generally are committed to agency discretion by
law and not judicially reviewable,300 judicial review is warranted when
an agency has completely abdicated its enforcement responsibility.2 0'
When an agency's failure to observe its own regulations or procedures
results in prejudice to the parties the regulations and procedures were
designed to protect, the courts will force the federal agency to comply
strictly with the guidelines set.302
The Supreme Court has been concerned that allowing judicial re-
view of agency determinations would substitute the courts' assessment
of which enforcement actions should take precedence for that of the
297. See Cotton, 263 JAMA at 1049-50 (cited in note 4).
298. See note 97.
299. This is especially true since women are their best customers. Hamilton and Parry, J.
Am. Med. Women's Ass'n at 126 (cited in note 2).
300. See Heckler v. Chaney, 470 U.S. 821, 837 (1985).
301. Adams v. Richardson, 480 F.2d 1159, 1163 (D.C. Cir. 1973). In Adams v. Richardson,
the court held that the Secretary of Health, Education and Welfare's decision to encourage volun-
tary compliance with desegregation orders was an abdication of its statutory duty. Id. at 1164.
The Supreme Court cited this decision in Heckler, 470 U.S. at 833 n.4. Although the Court
stated that judicial review of enforcement decisions generally was not permissible, it expressed no
opinion as to whether, when the agency decisions regarding enforcement amounted to an abdica-
tion of the agency's duty, review might be appropriate. Id.
302. Baltimore v. Mathews, 562 F.2d 914, 922 n.6 (4th Cir. 1977) rev'd on other grounds, 571
F.2d 1273 (4th Cir. 1978).
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agency."' 3 In the context of normal enforcement decisions, this concern
is valid. However, in the context of an agency's failure to act pursuant
to its statutory duty, or even when the agency merely ignores its oppor-
tunities to act, 04 the agency is not making policy determinations.
Rather, it simply is deciding not to act at all, under any circumstances.
In such a situation, the intervention of the courts is appropriate.3 0 5
The NIH already has made its policy decision. Before the NIH will
fund an applicant, the applicant must show that the proposed study
includes women or that a very good reason exists why women are not
included.3 0 This requirement is a condition precedent to the receipt of
an NIH grant. 0 7 Any decision on the part of the NIH not to enforce its
policy is, therefore, a failure of this agency to adhere to its own criteria.
Once an agency sets its procedural requirements, those require-
ments operate as if they were statutory mandates for the agency.3 08 The
NIH's failure to adhere to its own policy is an abdication of its statu-
tory duty-an abdication that injures the very people the policy was
designed to protect. Furthermore, even if the NIH were to assume that
researchers voluntarily would include women in their studies, as the
FDA has assumed vis-a-vis pharmaceutical houses,30 9 this assumption
still would not satisfy the legal requirements surrounding enforcement
decisions. It is simply not enough to hope that a policy will be self-
actualizing.310 The agency must act, at least to some degree, to imple-
ment and to bring about adherence to the agency policy.311 One way to
assure the inclusion of women would be to enlist the aid of the courts in
forcing the NIH to follow its own policy decisions.
2. FDA Guidelines-Encouraging a More Balanced Solution
According to one spokesman at the FDA, the agency has become
aware, in the light of Johnson Controls, that a liberty interest may exist
303. See Heckler, 470 U.S. at 830-32.
304. See Adams, 480 F.2d at 1164.
305. See id.
306. See text accompanying note 128.
307. Id.
308. Mathews, 562 F.2d at 920.
309. Cotton, 263 JAMA at 1050 (cited in note 4) (quoting a representative from the Pharma-
ceutical Manufacturer's Association); Telephone interview with Dr. Robert Temple (cited in note
43) (stating that the pharmaceutical companies are concerned about the bottom line and do not
want to alienate a large portion of their consumer base).
310. See Adams, 480 F.2d at 1164 (noting that the Department of Health, Education, and
Welfare made no formal complaints, did not file any enforcement proceedings, and did not refer





in allowing fertile women to participate in clinical trials. 12 Further-
more, he states that the FDA is willing to modify its Guidelines in order
to comport with current scientific knowledge and with women's inter-
ests in adequate health care.313 Moreover, he predicts that the GAO will
find that women, even fertile ones, have been included in clinical trials
all along.3 14 What is clear, however, is that fertile women have not been
included in the early phases of clinical research, a practice that the
FDA acknowledges may be due to a lack of understanding of the differ-
ences between the male and female physiology.3 15
The FDA should be encouraged to modify its Guidelines to provide
a more tailored approach for pharmaceutical companies and researchers
to follow. If products, such as antidepressants, are to be used predomi-
nantly by females, and the effects of those drugs will vary with the
menstrual cycle,31 then the FDA Guidelines should be flexible enough
to allow fertile women to be included in all phases of the study. The
clinical study populations should accurately reflect the populations that
will be using the drugs.3 17 Currently, there is little knowledge about how
the menstrual cycle affects the pharmacokinetics of many products reg-
ularly used by women.31 8 A guideline which requires gender differences
to be delineated and which provides for the inclusion of fertile women
in all phases of clinical trials would better account for the differences
between the genders, differences that are more significant than origi-
nally thought.3 1 9 It is precisely because of these differences that the
medical community believes women, especially fertile women, should be
included in all stages of clinical research.32 0 The changes to the guide-
lines currently proposed by the FDA321 will be an improvement over the
existing guidelines. Nevertheless, they are insufficient to address the
breadth of the problem facing women and their doctors.
B. Economic/Market Solution-Encouraging the Drug
Manufacturers
The FDA realizes that pharmaceutical manufacturers are con-
cerned with their own economic well being.3 22 Thus, the FDA believes




316. See, for example, Raskin, 159 J. Nerv. & Ment. Dis. at 120 (cited in note 1).
317. Cotton, 263 JAMA at 1050 (cited in note 4) (quoting Dr. Sidney Wolfe).
318. See note 28 and accompanying text; part II.B.
319. See Council on Ethical and Judicial Affairs, 266 JAMA at 559 (cited in note 5).
320. Id.
321. See notes 207-08 and accompanying text.
322. See Cotton, 263 JAMA at 1049. This is only natural since pharmaceutical companies are
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that the pharmaceutical manufacturers will include populations that re-
flect the actual consumers of their products.32 3 This belief, however, has
not been borne out by practice.
32 4
Yet, if pharmaceutical houses were convinced that by failing to
study women's reactions to their products, they would suffer exposure
to tort liability and added expense, then they would likely work to in-
sure that women are included in their sample populations. Neverthe-
less, merely including women is not a satisfactory result unless
differences between men and women also are studied. Competition in
the international market could go a long way to encourage this result.
Currently, the Japanese pharmaceutical houses are working to delineate
differences between the genders and among the races. ' 5 American and
Swiss manufacturers, however, are conducting business as usual 26 Al-
though the American and Swiss manufacturers currently control the
majority of the pharmaceutical market in this country, that statistic
could change. As one commentator has observed, pharmaceutical
houses could make a fortune tailoring their products to women's
cycles.327
VI. CONCLUSION
Regardless of the ostensibly noble reasons for the exclusion of
women from clinical trials, the net result has been inferior health care
for women. Women's health care has suffered from the lack of knowl-
edge about women's physiology and from the production of drugs which
are ill-suited for women's cycles.
Bernadine Healy, the new director of the NIH, has argued force-
fully for the inclusion of women in clinical research, stating that medi-
cal researchers should undertake broad exploration and dismiss useless
forms of discrimination. It is naive, she argues, to hope that the num-
bers of women currently entering the research fields will begin to cor-
rect these discrepencies on their own. Rather, it is necessary to train
those in the medical profession to look for the differences between the
genders.2 s
To this end, the FDA and the NIH, along with pharmaceutical
in business to make money.
323. Cotton, 263 JAMA at 1049.
324. Id.; Council on Ethical and Judicial Affairs, 266 JAMA at 559.
325. Cotton, 263 JAMA at 1050 (cited in note 4).
326. Id. (quoting Werner Kalow, MD, professor emeritus in the University of Toronto phar-
macology department: "American and Swiss manufacturers couldn't care less").
327. Cotton, 263 JAMA at 1055 (cited in note 20) (quoting Michelle Harrison, M.D., assis-
tant professor of psychiatry, University of Pittsburgh).
328. Healy, 266 JAMA at 566 (cited in note 129).
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manufacturers, should be encouraged to create test populations in their
clinical trials that reflect the populations affected. If the pharmaceuti-
cal houses and researchers actively begin to deliniate gender differences,
the net gain will be significant, not just for women's health care, but for
the health of the nation.
The legal community is in a position to encourage this action
through litigation, forcing the NIH actively to implement its policy
mandating the inclusion of women and to conduct mandatory studies to
differentiate gender responses. Additionally, the legal community can
address the equal protection questions surrounding the FDA's Guide-
lines. If the FDA could be convinced that it needs to alter its Guide-
lines to comport with equal protection principles, steps could be taken
to insure that women are included in study populations to the extent
that they are consumers of the drugs. As a result, pharmaceutical man-
ufacturers would be forced to include women in their test populations
before releasing a drug onto the market. Finally, the legal community is
in a strong position to make clear to pharmaceutical houses that they
face potential tort liability for the inferior process by which their drugs
are tested, regardless of any action by the FDA.
Ultimately, however, Congress is in the best position to mandate a
health care initiative for women. Congress should be encouraged to pass
the Women's Health Equity Act, which would improve the methodology
of health care research. The Act would provide both the mandate and
the funding for the NIH study of women's diseases. This statement of
congressional intent would go a long way toward effecting the goal of
providing equitable health care for women and would provide a forum
through which the complex issues surrounding the safe use of women in
clinical trials could be more effectively addressed.
L. Elizabeth Bowles*
* The Author would like to thank Professor Ellen Wright-Clayton, J.D., M.D., for her help
on an earlier version of this Note.
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